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ABBREVIATIONS 
AIP   aryl hydrocarbon receptor interacting protein 
cAMP   cyclic adenosine monophosphate 
cGMP   cyclic guanidine monophosphate 
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GNAS   guanine nucleotide-	
	 
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GSK3  glycogen synthase kinase 3  
IGF-1   insulin-like growth factor 1 
JNK   c-Jun NH2-terminal kinase 
LAR   long-acting release 
MAP(K)  mitogen activated protein (kinase) 
MEN-1  Multiple Endocrine Neoplasia type 1 
MMP   matrix metalloprotease 
MRI   magnetic resonance imaging 
mRNA  messenger ribonucleic acid  
   		 
NMT   neuroendocrine-to-mesenchymal transition 
NO   nitric oxide 
NOS   nitric oxide synthase 
NPV   negative predictive value 
PDE4A5  phosphodiesterase-4A5 
   phosphatidylethanolamine binding protein 
4 
 
PGE2    prostaglandin E2 
PI3K   phosphatidylinositol 3-kinase 
PKC   protein kinase C 
PKAR1A  protein kinase A type 1-
		 
PPV   positive predictive value 
ptd-FGFR4  pituitary tumour-derived fibroblast growth factor receptor 4 
PTP   phosphotyrosine protein phosphatases 
PTTG   pituitary tumour transforming gene 
RKIP   Raf kinase inhibitory protein 
SHP-1/2  Src homology domain phosphatase-1/2 
SMR   standard mortality rate 
SMS   somatostatin 
SSTR   somatostatin receptor 
TGF-   			 

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"#$  zinc finger E-box binding homeobox 1/2 
VEGF   vascular endothelial growth factor 
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INTRODUCTION 
Acromegaly 
General 
Definition and epidemiology 
The first historical description of acromegaly could be the story of David and Goliath 
described both in The Old Testament and in the Koran. Goliath was a giant, but David 
defeated him by sneaking up on him, maybe in his visual field defect, and hitting him with a 
stone in the forehead using a sling. The connection between gigantism and the pituitary, 
hence with the possibility of visual disturbances, was not recognized until 1884, published 
in a book by Fritzsche and Klebs. Two years later, Pierre Marie introduced the name 
acromegaly and a clinical description of the syndrome. He had several suggestions for the 
aetiology; none included the pituitary (1;2). 
Acromegaly is a clinical syndrome due to chronic exposure to supra-physiological 
levels of growth hormone (GH), in almost all cases caused by a GH producing somatotroph 
pituitary adenoma. When the GH overproduction occurs before the fusion of the growth 
plates, it results in increased and continuous length growth, termed gigantism (3). However, 
the disease usually develops later in life, with a median age of diagnosis at 40-50 years (4-
8), men being a little younger than females (5;6;8). The incidence of acromegaly is reported 
to be 2-4 new cases per million inhabitants per year (4-7), but the prevalence is markedly 
higher, varying between 36 and 125 patients per million inhabitants in recent publications 
(5;7;9;10). The reports with the lowest numbers for both incidence and prevalence are from 
national registers of acromegaly, where the results from different regions are highly 
variable. This could be due to registration bias and underestimation in some of the regions, 
and hence an underestimation of total incidence and prevalence.  
Clinical characteristics 
The clinical features and symptoms of acromegaly develop slowly, and the diagnosis is 
usually delayed by several years. The median time from start of symptoms to diagnosis has 
been reported to 4 to 6 years in recent studies (7-11). This diagnostic delay did not change 
in patients diagnosed between 1992 and 2003, compared to 1981 – 1991 (11). A published 
patient’s journey is an illustrating example of how long the way to correct diagnosis can be 
8 
 
(12). The symptoms of acromegaly are due to tumour mass or hormone hypersecretion. The 
symptoms caused by the expanding tumour mass are similar for all pituitary tumours, and 
include headache and compression of the optic nerve tract or chiasm causing visual field 
defects. In larger adenomas, various degrees of pituitary insufficiency can occur due to 
suppression of the other hormone producing cells in the pituitary. The elevated level of GH 
leads to increased production of insulin-like growth factor 1 (IGF-1), both in the liver 
causing increased systemic IGF-1, and locally. The effects of elevated GH and IGF-1 
include acral and soft tissue hyperplasia, causing enlarged and swollen hands and feet, 
carpal tunnel syndrome, coarse facial features and macrognathia, macroglossia, sleep 
apnoea and deepening of the voice. Arthropathy with joint pain is common, developing to 
irreversible osteoarthritis in a later stage. Metabolic changes like increased insulin resistance 
causing impaired glucose tolerance or diabetes mellitus are not unusual. Commonly 
reported are also increased sweating, fatigue and physical weakness. A recent study reported  
higher incidence of affective disorders, particularly depressions, in patients with 
acromegaly, also compared to patients with other chronic diseases. Cardiac hypertrophy 
occurs even in patients shortly exposed to GH hypersecretion, and can develop further to 
cardiomyopathy and heart failure in untreated acromegaly. Arterial hypertension, 
arrhythmias and atherosclerosis are other manifestations (3;11;13-15). A schematic 
overview of symptoms is given in table 1. 
Diagnosis 
Single GH measurements are not reliable in the diagnostic evaluation of acromegaly due to 
the normal pulsatile GH secretion. However, IGF-1 is a function of the integrated 24-h 
serum GH level and a single measure can be used as screening procedure. In acromegaly, 
serum IGF-1 will be elevated compared to the normal age related reference range. The 
diagnosis are confirmed with an oral glucose tolerance test (OGTT), where hyperglycaemia 
will fail to suppress GH sufficiently in the case of acromegaly (3). A magnetic resonance 
imaging (MRI) scan of the pituitary will usually identify the adenoma. 
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Table 1. Symptoms of acromegaly 
Local tumour effects 
Pituitary enlargement 
Visual field defects 
Hypopituitarism (i.e. menstrual disturbances, infertility) 
Hyperprolactinaemia with galactorrhea 
Headache 
Cranial nerve palsy 
Systemic effects 
General 
Fatigue 
Affective disorders 
	=		 
Acral enlargement 
Coarse facial features 
Arthralgia  
Osteoarthritis 
Carpal tunnel syndrome 
Prognathism and jaw malocclusion 
Visceromegaly (i.e. tongue, thyroid gland) 
Skin and gastrointestinal system 
Excessive sweating 
Increased skin thickness 
Skin tags 
Colonic polyps 
Cardiovascular system 
Hypertension 
Arrhythmias 
Ventricular and septal hypertrophy 
Diastolic dysfunction and heart failure 
Endothelial dysfunction 
Pulmonary system 
Upper airway obstruction 
Sleep apnea 
Metabolism 
Impaired fasting glucose and glucose tolerance 
Insulin resistance 
Diabetes mellitus 
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Pathology of the somatotroph pituitary adenoma 
General 
Growth hormone production in the normal somatotroph cell is regulated through growth 
hormone releasing hormone (GHRH) and somatostatin, both secreted by cells in the 
hypothalamus. GHRH binds to its own receptor at the surface of the somatotroph cell, and a 
stimulatory G-protein is activated, leading to increased production of the intracellular 
second messenger cyclic adenosine monophosphate (cAMP). Through subsequent activation 
of intracellular protein kinases, this results in cell proliferation and growth hormone 
synthesis and secretion (16). Somatostatin inhibits GH secretion through activation of an 
inhibitory G-protein after binding to the somatostatin receptor (16;17). 
 Tumours in the pituitary can arise from all the different cell types in the anterior 
lobe. GH producing adenomas, the somatotroph pituitary adenomas, are tumours of the 
somatotroph cell line. They are considered benign tumours, as they usually grow slowly and 
metastasize extremely seldom, but they can be locally invasive. The growth of these 
adenomas are monoclonal. Yet, mutations in classical oncogenes or tumour suppressor 
genes found in other neoplasms have not been detected (16-19). Pituitary tumours are 
generally sporadic, but up to 4-5 % of patients may have an adenoma as part of a familial 
syndrome like Multiple Endocrine Neoplasia type 1 (MEN1) with mutation in the MEN1 
gene, Carney complex with mutation in the PRKAR1A gene or McCune-Albright syndrome 
with somatic mutations in GNAS (17;19;20). Familial isolated pituitary adenomas (FIPA) 
have also been described, representing about 1 % of all pituitary adenomas (20;21). After a 
genetic linkage study suggested a candidate locus on chromosome 11, a Finnish group 
identified germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) 
associated with familial presentation of somatotroph and lactotroph pituitary adenomas 
(22;23). Till now, at least 33 different AIP mutations have been detected, and they account 
for approximately 15 % of the FIPAs, but higher in families with exclusively somatotroph 
adenomas. The penetrance of disease in the AIP mutation positive families was low in the 
original publication, but later studies conclude with a penetrance of at least 33 % 
(20;21;23;24). A recent publication suggested existence of modifier genes that can explain 
the observed variability in phenotype between the mutation positive persons in a family 
(25). The mutant AIPs have a lower ability to bind to its known interacting partner 
PDE4A5, thereby affecting its effect to modulate cAMP (20;21;24). In the study from 
Finland, the same AIP mutation was detected also in 16 % of sporadic acromegaly patients 
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(23). This has not been confirmed in other studies, where germline mutations have been 
found in none or very few of the patients with sporadic acromegaly (20;21;24). The patients 
with an AIP mutation seem to be younger at the onset of disease, also compared to other 
FIPA patients (23;24). 
Gsp oncogene 
]			^]%'			=		^
				^-protein linking 
the GHRH-R to adenylyl cyclase, are designated gsp oncogene. They are reported to exist in 
approximately 40% of the sporadic somatotroph adenomas. This mutation, found in the 
=			=	$_"		$$`'						^
	=		
increased production of the intracellular second messenger cAMP. The result is cell 
proliferation and growth hormone synthesis and secretion (26-28). Patients with a gsp 
positive adenoma do not differ in age and sex compared to patients with gsp negative 
adenomas. Studies correlating the gsp status to clinical variables like GH level and tumour 
size have not been conclusive, although most studies suggest that gsp positive adenomas are 
smaller than gsp negative adenomas (29-34). Most, but not all studies found a better in vitro 
or acute octreotide response in gsp positive adenomas (29;30;32-37) compared to tumours 
without this mutation. The two studies of long-term octreotide response in 18 and 42 
patients did also conclude with a better GH response during octreotide treatment in patients 
with gsp positive adenomas, but no difference in IGF-1 response in the one study presenting 
these data (29;38). 
Morphology 
The somatotroph pituitary adenomas have morphologically been classified into two types; 
densely and sparsely granulated somatotroph adenomas. At the ultrastuctural level, the 
densely granulated adenomas have extensively developed rough endoplasmatic reticulum 
and Golgi complex, and numerous large secretory granules. Histologically, they are 
acidophilic and show strong immunostaining for GH. They can also show immunoreactivity 
	Z			
-subunit of glycoprotein hormones. The sparsely granulated adenomas, 
on the other hand, are chromofobic and show none or only weak positivity for GH by 
immunohistochemistry. In the electron microscope, they have few and small secretory 
granules and the Golgi apparatus is often replaced by a fibrous body (39). The fibrous 
bodies are dense aggregates of cytokeratin filaments and are considered a marker of sparsely 
granulated adenomas. The fibrous bodies can be demonstrated as dot-like appearances by 
immunohistochemistry for cytokeratin, in contrast to the densely granulated adenomas that 
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display a diffuse perinuclear staining pattern (39-41). In the first study of gsp oncogene and 
adenoma morphology, there was a high concordance where all the eight gsp positive 
adenomas were densely granulated and six out of nine gsp negative adenomas were sparsely 
granulated (33). In a recent study, the 14 sparsely granulated adenomas were gsp negative, 
while five of the 12 densely granulated adenomas harboured the mutation (42). So far, no 
other correlations have been performed between adenoma morphology and gsp mutation. In 
addition, an intermediate group has been described?	oth a mixed population of the two 
described patterns and transitional patterns of cytokeratin staining with borderline shapes 
with neither pure perinuclear nor dot-like appearances have been described in a substantial 
proportion of adenomas (40). The normal adenohypophysial cells show the perinuclear 
pattern in immunostaining with an anti-cytokeratin antibody (40), and it is demonstrated that 
densely granulated adenomas transform and develop fibrous bodies after in vitro exposure 
to pegvisomant (42). One theory can be that the gsp positive adenomas remain densely 
granulated, but that the gsp negative adenomas can develop fibrous bodies and a sparsely 
granulated morphology parallel with a dedifferentiation. Studies have indicated that the 
densely granulated adenomas respond better to somatostatin analogue treatment (43;44), and 
that the sparsely granulated adenomas are more often macroadenomas and invasive (40;41). 
In addition, downregulation of the adhesion protein E-cadherin is demonstrated particularly 
in the sparsely granulated adenomas (40;45;46).  
Growth factors and cell cycle control 
Several cell cycle inhibitors are shown to be reduced in pituitary adenomas, in particular the 
cyclin-dependent kinase p27Kip1. p27 regulates the progression of G1 to S phase in the cell 
cycle. Reduced protein levels of p27 has been demonstrated in pituitary tumours, but mainly 
in corticotroph adenomas and carcinomas, and negatively correlated to the proliferation 
marker Ki-67 (19;47-49). Interestingly, p27 protein levels were upregulated in pituitary 
adenomas after in vitro treatment with somatostatin analogues (50). Possible mechanisms 
for the importance of p27 in the somatostatin analogue response are further elaborated in the 
somatostatin analogue and receptor section (p. 20). Another cell cycle regulator is the 
pituitary tumour transforming gene (PTTG) which is overexpressed in pituitary tumours, 
and is correlated to invasiveness and Ki-67 expression (16;19). Alterations in the expression 
of growth factors like epidermal growth factor (EGF) and fibroblast growth factors (FGFs) 
and their receptors EGFR and FGFRs might have roles in the adenoma growth. The 
activated phosphorylated EGFR has been found in pituitary adenomas and with higher 
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levels in carcinomas. One study demonstrated higher levels of EGFR in recurrent 
somatotroph adenomas (51;52). A truncated kinase-containing variant of FGFR4 has been 
found in pituitary adenomas, termed ptd-FGFR4 (53). This is detected in the cytoplasm, in 
contrast to wild-type FGFR4 which is located to the cell membrane, and correlated to the 
expression of Ki-67. One study of all pituitary adenoma types has indicated that ptd-FGFR4 
is higher in macroadenomas, but a smaller study of somatotrophs could not confirm this 
(54;55). 
 
Treatment of acromegaly 
Rationale for treatment 
Overall, mortality is increased by approximately 70 % in acromegaly, as given in two recent 
meta-analyses (56;57). This is mainly due to the effect of excess GH on the cardiovascular 
system (13;57). The correlation between acromegaly and malignancy is more controversial, 
but in a nationwide survey from Finland a significant higher cancer incidence (colorectal 
and thyroid cancer) was found in patients with acromegaly compared to the general 
population. For colorectal cancers, this was only in the group of Z		^<	{	$?|	}#	
after treatment (58). In both meta-analyses, the patients successfully treated with 
		^<			$?|	}#	=					the reference level. 
Standard mortality rate (SMR) for the patients with GH {	$?|	}#	after treatment was 1.9 
(95 % confidence interval 1.5-2.4), (57). Although more debated, this was analysed with 
respect to the IGF-1 level in one of the meta-analyses, with SMR 2.5 (1.6-4.0) for patients 
with elevated IGF-1 (57). Therefore, effective treatment of acromegaly with normalization 
of hormone levels is important to restore normal life expectancy in addition to controlling 
tumour growth and to relieve symptoms for the patient. 
Surgery 
The first attempts of surgical resection of pituitary adenomas were performed in the 
beginning of the 20th century, but with high mortality rates. Dr. Schloffer did the first 
successful removal of an adenoma by transsphenoidal, transnasal approach in 1907, and the 
procedure was later modified by Harvey Cushing and others. Despite only about 5 % 
mortality rate of Cushing’s large series of transsphenoidal adenomectomy from 1910 to 
1925, he also modified the transfrontal approach. From 1930 Cushing abandoned the 
transsphenoidal technique, and for the next 35 years it was in little use. Guiot and Hardy 
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developed the method further with illumination of the surgical site and an operating 
microscope, and from the late 1960ies the method had its renaissance (59;60). Today, 
transsphenoidal adenomectomy is still the primary treatment of most patients with 
acromegaly (61). While overall surgical cure rate has been reported as high as 52-57 % in 
series from particularly experienced neurosurgeons, microadenomas 75-82 % and 
macroadenomas 47-50% (62;63), recent reports from national or regional surveys with the 
same stringent criteria for cure show a marked lower cure rate. They report an overall cure 
rate of 30-40 %, but with large variation between the included centres (4;5;7;64). The 
results are best in the hands of a particularly interested neurosurgeon (65;66).  
Radiotherapy 
Radiotherapy of the adenoma was previously used more regularly, but today it is mostly 
used if tumour growth control and normalization of hormone levels cannot be obtained by 
surgery and medical treatment (5;61)?			=	=	apy and 
stereotactic radiotherapy (i.e. gamma knife) are used. The mortality is shown to be 
particularly high in radiated patients. This can partly be due to the resistant acromegaly in 
these patients, but also due to consequences of radiation therapy like hypopituitarism 
(5;6;67;68). 
Medical treatment; dopamine agonist 
The first successful report of medical treatment in acromegaly was the study of L-dopa 
treatment of eight patients published in 1972 (69). All patients responded with GH 
reduction, and two patients reached normal GH levels. When bromocriptin later was shown 
to be a dopamine agonist, the same group demonstrated a GH lowering response to oral 
intake of bromocriptin in the seven patients studied (70). Today, cabergoline is the 
dopamine agonist most used, and the advantages are the relatively low cost and the oral 
administration. However, hormone levels can be controlled only in approximately one third 
of patients treated with a dopamine agonist in monotherapy (71-73). Nevertheless, 
cabergoline can be used in combination with other drugs, particularly somatostatin 
analogues. In patients with inadequate response to treatment with somatostatin analogues, 
addition of cabergoline led to normalization of hormone levels in 40-50 % of the patients 
(74-76). The clinical response to dopamine agonist treatment was better in patients with 
elevated S-prolactin in one study and in patients with adenomas showing positive 
immunostaining for prolactin in another study (72;76). Newer and larger studies have not 
found a correlation between clinical cabergoline response and baseline S-prolactin level or 
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prolactin immunostaining of the adenoma (73-75). The clinical response to dopamine 
agonist treatment is probably related to the expression of dopamine receptor 2 (D2R) in the 
tumour. One study has demonstrated such a correlation between immunohistochemical 
expression of D2R and the in vitro response to quinagolide, but there was no correlation to 
the in vivo response during an acute quinagolide test. Nevertheless, this study demonstrated 
that D2R is expressed both in mixed GH/prolactin adenomas and also in pure GH secreting 
adenomas (77). 
Medical treatment; growth hormone receptor antagonist  
The structures of GH and the GH receptor (GHR) and the receptor binding parts of the GH 
molecule were discovered in the late 1980ies. Following, the important dimerization of the 
GHR upon binding of the ligand was discovered (78), and the development of mutant GH 
analogues and studies of the ability of these to inhibit growth in transgene mouse led to the 
discovery a GH antagonist (78-83). Pegvisomant is a GHR antagonist with a single amino 
acid substitution in position 120 to inhibit the receptor dimerization important for 
downstream signalling, and substitution of eight amino acids in the binding site to increase 
affinity. For clinical use, the molecule is pegylated to increase biological half-time (82). 
Pegvisomant acts in the periphery and not on the pituitary tumour like the other drugs used 
in the treatment for acromegaly. Therefore, measurements of GH can not be used in the 
clinical evaluation of treatment response. The efficacy of this compound in reducing serum 
IGF-1 has been reported to 71-97 %, and it significantly reduces the symptoms of 
acromegaly. Reported adverse effects have been reversible liver transaminase elevations and 
growth of the pituitary tumour; the latter being seldomly observed (84-88). In a large 
German observational study of more than 300 patients (83 % of all patients receiving 
pegvisomant treatment in Germany), tumour volume increased during treatment in only nine 
patients and discontinuation of the treatment was necessary in only three patients (84). The 
major reason for the limited use of pegvisomant so far is probably the high costs. Therefore, 
combination treatment of pegvisomant and somatostatin analogues is increasingly used, 
allowing reduced doses of pegvisomant, often with a twice-weekly administration. This is as 
efficient as pegvisomant monotherapy (89;90). 
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Somatostatin and the somatostatin receptor 
Somatostatin treatment 
Somatostatin analogue development 
A hypothalamic peptide inhibiting the release of GH from the pituitary was detected in 
1973, designated somatostatin (SMS)?			ovine and synthetic somatostatin 
inhibited GH secretion in rats when administrated intravenously, and in vitro native 
somatostatin significantly diminished GH secretion in pituitary adenoma cells from a patient 
with acromegaly (91). The first studies of somatostatin administration in healthy individuals 
and acromegaly patients demonstrating GH lowering effects were performed the same year 
(92;93). However, native somatostatin has very short biological half-life (2-3 minutes) 
which complicates its use in a clinical setting, and in addition there were disadvantages with 
rebound hypersecretion of hormones. The development of long-acting somatostatin 
analogues was therefore important, and octreotide (SMS 201-995) was presented in 1982 
(94). The first clinical tests with this analogue demonstrated strong GH inhibition in 6/7 and 
7/8 patients in up to 10 hours after injection, with no rebound GH response and only short-
time insulin lowering effect that declined after repeated dosing (95;96). Three days 
treatment with octreotide 2-3x daily gave reduction in GH levels by 30-79%, and two 
patients were treated for several months with sustained GH reduction and improvement of 
symptoms yet no side effects (97). Later, a long-acting release octreotide (Octreotide LAR) 
and the equivalent analogue lanreotide (Lanreotide Autogel) have been developed, allowing 
a dosing interval of approximately four weeks. Today, these somatostatin analogues are 
widely used in the treatment of acromegaly, and are regarded as the first-line drugs in the 
medical treatment of this disease (61). 
Clinical treatment 
The clinical response to treatment is highly variable. Some patients respond well with 
normalization of hormone levels and regression of the tumour, while other patients 
experience increasing hormone levels and tumour size. Studies of clinical biochemical 
response to long-term somatostatin analogue treatment have included very different patient 
groups and have used different definitions of disease control (98). A few studies have 
included only unselected de novo patients who have not received prior treatment. In these, 
biochemical control is achieved in 20, 25, 27 and 50 % of patients, with biochemical control 
defined as a mean GH below 2-$?|	}#	=			~^-1 for age. (99-102). Mean overall 
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tumour shrinkage in unselected, primarily treated patients has been reported to be 25-40 % 
(99-102). Meta-analyses of studies with primarily treated patients (unselected and selected) 
have concluded with 20 and 50% mean shrinkage (99;103), but individually the tumour 
volume reduction is highly variable, ranging from +13 to -100 % (104;105). There is no 
correlation between biochemical response and tumour shrinkage (99;101;105;106).  
 
Somatostatin receptors and signalling 
Somatostatin receptors and their expression 
The somatostatin analogues exert their effects through binding to the somatostatin receptor 
(SSTR) localized in the cell membrane. The somatostatin receptor was first characterized in 
1978 when it was shown that the receptor was necessary for somatostatin to exert its 
biological activities (107). In the 1980ies, studies demonstrated the existence of more than 
one SSTR subclass (108;109), and in the early 90ies the five receptor subtypes were cloned 
(110-112). These were named somatostatin receptor 1-5 (SSTR1-5). The genes for each 
receptor are located on different chromosomes, but with partial sequence homology. There 
is also a high degree of structural conservation across species. All receptor subtypes are 
transmembrane G-protein coupled receptors. Except for SSTR4 they are all glycosylated, 
which explains the observed variation in protein size on immunoblots. The SSTR2 gene 
encodes two variants of the protein, SSTR2a and 2b, due to alternative splicing. They differ 
only in the length of the cytoplasmic tail (113;114). One study indicates that SSTR2b binds 
with higher affinity to the downstream signalling molecules and that it may be less 
susceptible for desensitization (115). However, in the human pituitary and specifically in 
somatotroph adenomas, SSTR2a dominates (116;117). The SSTRs are widely distributed 
throughout many tissues and in various cancer cells, but in a species and cell specific pattern 
(113;114). In the human pituitary and in somatotroph adenomas, messenger RNA (mRNA) 
for the four subtypes SSTR1, 2, 3 and 5 are expressed, but SSTR 2 and 5 dominate 
(118;119). More recently, this was confirmed at the protein level in a immunohistochemical 
study, while another study found positive staining for all SSTRs in the somatotroph 
adenomas (120;121). Nevertheless, the individual patterns of subtype expression are highly 
variable even among the somatotroph adenomas. 
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Signal transduction and molecular responses 
%			%%		ZY?	=		=				Z	
activates a variety of cellular responses through activation of specific G-proteins coupled to 
different intracellular signalling pathways. Each receptor subtype is coupled to multiple 
second messenger systems, some are common for all subtypes and some are subtype 
specific. All receptor subtypes are potent inhibitors of adenylyl cyclase and cAMP 
formation, and all activate phosphotyrosine protein phosphatases (PTP). All receptors also 
modulate the mitogen activated protein (MAP) kinase signalling pathway, phospholipase C 
and the K+ ion channels. Most also influence the Ca2+ ion channels, in addition to nitric 
oxide (NO) and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (98;113;114;122). 
Table 2 gives a detailed overview of the signals from each receptor subtype. 
 
Table 2. Somatostatin receptor signalling 
Transduction pathway SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 
Adenylyl cyclase      
Ca2+ channels      
K+ channels      
Phospholipase C     # 
Phospholipase A2      
PTPs      
PI3 kinase/Akt  #    
Nitric oxide/cGMP  #    
Na+/H+ exchange    #  
ERK (MAP kinase) # # #   
Responses      
GH secretion      
Cell proliferation    #  
Apoptosis      
Patel YC (1999), Pyronnet S et al (2008) and Weckbecker G et al (2003) (113;114;122). 
 
As mentioned above, several studies have demonstrated lack of correlation between 
biochemical response and tumour shrinkage during treatment with a somatostatin analogue 
in acromegaly. This suggests that different mechanisms are responsible for the antihormone 
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and the antitumour response (123). Figure 1 is a simplified map over the somatostatin 
receptor responses. The pathways of the responses in the somatotroph adenomas can be 
divided into the following categories; 
1) Antisecretory response 
Somatostatin inhibits the secretion, but not the production of GH (122). The inhibition of 
GH secretion in the somatotroph adenomas is mediated by the inhibition of adenylyl cyclase 
and reduction in cAMP, but probably more important, by a decrease in intracellular Ca2+. 
The reduced intracellular Ca2+ is a result of opening of K+ channels or inhibition of Ca2+ 
channels. Reduced secretion could also be mediated by a serine/threonine phosphatase. It 
has been suggested that SSTR1, 2 and 5 are responsible for the antisecretory effects of 
somatostatin (113;122;124). 
2) Antitumour responses 
a) Indirect antitumour effects 
Somatostatin inhibits tumour growth by inhibition of growth factors like IGF-1 and EGF, in 
addition to inhibition of angiogenesis (114;122). The somatotroph pituitary adenomas 
express increased levels of angiogenic markers like FGF-2 and vascular endothelial growth 
factor (VEGF) (125), and in vitro treatment with the somatostatin analogue pasireotide led 
to decreased VEGF and reduced cell viability in non-functioning pituitary adenomas. This 
effect was not mediated by SSTR5 despite the high affinity of pasireotide to SSTR5, 
because the responder group did not express this receptor subtype (126). It has also been 
shown that proliferating, but not resting, endothelium express SSTR2 and 5, and in vitro 
treatment with both SSTR2 and 5 preferring analogues resulted in reduced proliferation of 
the endothelial cells (127). SSTR3 can also be involved, as one study demonstrated that 
SSTR3 mediated inhibition of angiogenesis through inhibition of MAPK and endothelial 
nitric oxide synthase (eNOS) (128). 
b) Direct antitumour effects 
i) Induction of cell cycle arrest (cytostatic response) 
All five somatostatin receptors can mediate the antiproliferative response of somatostatin. 
The intracellular pathways involved are differently regulated according to receptor subtype 
and cell environment (114). However, all SSTRs are shown to activate PTPs and the altered 
cellular phosphorylation pattern triggers the further signalling (113). Activation of the PTP 
SHP-1 is demonstrated to be a critical step for SSTR2-mediated antiproliferative signalling 
(129). The PTP SHP-2 is probably involved in the interaction between SSTR2 and SHP-1 
(130). The activated SHP-1 dephosphorylates different signalling molecules, including nitric 
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oxide synthase (NOS), leading to increased p27. p27 is a cyclin-dependent kinase inhibitor 
that has an important role regulating entry into and exit from the cell cycle (50;131;132). 
SSTR5 can also increase p27, and both SSTR2 and 5 activation lead to reduction of cyclin 
D1, a cell cycle progression protein (133). Activated SHP-1 also induces increased cGMP 
via activation of NOS and the resulting nitric oxide, which also results in inhibition of cell 
proliferation (131). The similar response is seen downstream of SSTR5 activation (134). 
Via receptor tyrosine kinases, SSTR2, 3 and 5 inhibit the MAPK pathway which leads to 
inhibited cell proliferation (50;113;134).  
ii) Induction of apoptosis (cytotoxic response) 
Apoptosis is induced through activation of SSTR2 and SSTR3, both using mechanisms 
dependent on SHP-1 activation. SSTR3 promoted apoptosis is mediated through activation 
of wild-type tumour suppressor protein p53 and the pro-ZZ	Z	Y?	~=Z=	
of this, apoptosis is triggered by intracellular acidification due to activation of an acidic 
endonuclease in a SHP-1 dependent manner (135-137). SSTR2 also induces apoptosis 
dependent of SHP-1, but independent of p53 (138). SSTR2 sensitizes the cells to apoptosis 
==		=	=	@	
	through stimulation of NF	by upregulating their 
receptors and inhibition of the MAPK JNK (139;140). Activation of SSTR2 also results in 
PI3K inactivation and induction of apoptosis (141). 
Internalization and degradation 
The G-protein-coupled receptors have the ability to regulate their responsiveness to 
continuous agonist exposure, with desensitization and uncoupling from the G-proteins and 
receptor internalization. After internalization, the receptors are either degraded or recycled 
back to the cell membrane. These mechanisms also apply to the human SSTRs, however, 
the regulation is subtype specific (113). SSTR3 and 5 display the highest degree of 
internalization, while SSTR1 do not internalize (142). While SSTR3 is a subject of 
degradation after internalization, SSTR2a is often recycled back to the cell membrane. The 
internalization of SSTR2a requires binding to -arrestin after phosphorylation of SSTR2a by 
G-protein-coupled receptor kinase 2 (GRK2) (143). 
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Figure 1. A simplified map over the main responses downstream of the somatostatin receptor. 
Modified from Weckbecker et al 2003 (122) . 
Tachyphylaxis 
Tachyphylaxis is the adaptation or escape of somatostatin effect after prolonged treatment. 
From a clinical point of view, tachyphylaxis is not a problem in the somatostatin analogue 
treatment of acromegaly, only very few cases have been reported (142;144;145). In the 
treatment of carcinoid tumours, however, tachyphylaxis is frequently observed. It has been 
suggested that expansion of carcinoid tumour cell clones lacking SSTR2 may be the 
explanation of tachyphylaxis rather than downregulation of the receptor, partly because of 
the relatively long time before the escape of effect (142). 
 
Factors influencing the SMS response 
As outlined above, the clinical response to treatment with a somatostatin analogue is highly 
variable. Most studies have concluded that the gsp positive adenomas show a better SMS 
response than the gsp negative adenomas, but only two of these studies have analysed the 
long-term octreotide efficacy. Since the somatostatin analogues available today bind with 
highest affinity to SSTR2, it is expected that the adenoma expression of this receptor is 
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important for the SMS response. However, most studies have examined the mRNA level of 
SSTR2a, and not the protein expression. The mRNA level is not necessary correlated to the 
protein level of the receptor (133;146). The first studies demonstrated a positive correlation 
between the response in an acute octreotide test and the uptake of radiolabelled octreotide 
(147;148). Later, three of four studies (9-16 patients) have found a positive correlation 
between the SSTR2 mRNA level and the reduction in GH during an acute somatostatin 
suppression test (36;37;118;149) and the effect of somatostatin analogue on GH secretion in 
vitro (36;118). In the two studies of long-term octreotide response (11 and 23 patients) only 
one found a positive correlation between SSTR2 mRNA level and the percentage reduction 
of GH and IGF-1 (150;151). Prior to our study, only one paper had correlated the SMS 
response to the protein expression of SSTR2a. This study of 22 patients found that 
adenomas with more than 50% of cells positively stained for SSTR2a by 
immunohistochemistry, responded better to an acute octreotide challenge (152). 
 
New somatostatin analogues 
Octreotide and lanreotide both have a high binding affinity for SSTR2, less affinity for 
subtype 5 and lowest affinity for subtype 3 (113). Recently, a new somatostatin analogue 
has been developed. This analogue, pasireotide (SOM230), has a broader receptor affinity 
with strongest binding to SSTR5, yet relatively high affinity for subtype 2 and 3, and lower 
for receptor subtype 1 (153;154). The acute response to pasireotide was significantly better 
than the octreotide response in three of 12 patients and comparable responses in eight 
patients (155). Yet, no studies of clinical long-term efficacy of pasireotide have been 
published, but the hopes are that this drug can be efficient in patients with inadequate 
response to the traditional somatostatin analogues. Similarly, studies indicate that 
pasireotide could get a role in the treatment of non-functioning and corticotroph pituitary 
adenomas which have very limited responses to octreotide and lanreotide (126;156-158). 
However, a very recent in vitro study has demonstrated that pasireotide antagonizes some of 
somatostatin’s actions on the intracellular signalling pathways downstream of SSTR2a. 
pasireotide may therefore not be considered as a pure somatostatin mimetic (159). Chimeric 
analogues binding to both SSTR2 and D2	~-23A387) or SSTR2, SSTR5 and D2R 
~-23A761) are also under development. In vitro studies have suggested a synergistic 
effect with these analogues, larger than the responses seen with subtype specific analogues 
and combinations of these, and good response also in cells from partial octreotide 
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responders (160-162). This could be mediated by the receptor homo- and heterodimerization 
induced by these multiple ligands, which lead to increased coupling to and inhibition of 
adenylyl cyclase (163). Another theory is that the different interaction between the ligand 
and its receptor allows prolonged stabilization of its active conformation or alters the rate of 
SSTR internalization (160).  
 
Raf kinase inhibitory protein (RKIP) 
RKIP and its functions 
Raf kinase inhibitory protein (RKIP) is a member of the phosphatidylethanolamine binding 
Z		 of evolutionarily conserved proteins without significant homology 
with other proteins. RKIP is widely expressed in different tissues, localized to the cytosol 
and at the plasma membrane (164). The protein was isolated only a decade ago, when it was 
shown to inhibit the MAP kinase signalling pathway Ras/Raf-1/MEK/ERK (165). RKIP 
modulates the pathway by binding to Raf-1, and inhibits Raf-1 phosphorylation and 
activation (165-167). This intracellular signalling pathway is involved in the control of cell 
proliferation and differentiation, cell death and apoptosis (165;168). RKIP can also inhibit 
>#>		=			-Raf (169), a protein shown to be overexpressed in 
non-functioning pituitary adenomas (170). Protein kinase C (PKC) phosphorylates RKIP, 
which then dissociates from Raf-1 and instead binds to and inhibits G protein-coupled 
receptor kinase 2 (GRK2) (171). This leads to decreased internalization and degradation of 
G-protein coupled receptors, and internalization of SSTR2a is shown to be dependent of 
GRK2-mediated phosphorylation of the receptor (143). Activation of PKC leads to 
enhanced signalling of the G-protein receptors both by removing an inhibitor from Raf-1, 
resulting in an enhanced MAPK signalling, and by blocking receptor internalization and 
degradation, thereby prolonging the receptor signal (171). Figure 2 gives an overview over 
these RKIP functions. 
Through its inhibition of the MAPK pathway, RKIP regulates the spindle checkpoint 
of the mitosis. Loss of RKIP with increased MAPK activity leads to suppression of the 
]		@	. The cells move faster through mitosis with partial suppression of 
the spindle checkpoint, resulting in increased probability for accumulation of chromosomal 
abnormalities (172). Moreover, when the NF-	Z		=				
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or other cytokines, RKIP antagonizes this activation through its interaction with upstream 
kinases (173). 
 
 
Figure 2. RKIP signalling 
 
RKIP and cancer 
In several cancer types, RKIP has been suggested to be a metastasis suppressor gene, where 
loss of RKIP is associated with metastasis development. Metastatic tissue has significantly 
lower RKIP levels compared to the primary tumour, poorly differentiated tumours have also 
low levels of RKIP, and benign tissue has the highest levels (174-179). Loss of RKIP 
predicted metastatic recurrence and was the strongest predictor for reduced survival in a 
study of colorectal cancer (180). Reduced RKIP has been correlated to poor survival also in 
gastrointestinal stromal tumours (GIST) (181). In prostate cancer, injection of cancer cells 
with RKIP overexpression into mice prostatic gland reduced the number of mice that 
developed metastasis by 70 % (174), whereas RKIP overexpression in malignant melanoma 
cells markedly reduced their invasion potential in vitro (176). Loss of RKIP has also been 
linked to resistance to chemotherapeutic drugs in prostate and breast cancer cell lines (182). 
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E-cadherin and epithelial-to-mesenchymal transition (EMT) 
E-cadherin 
Cadherins are a large family of more than 100 different glycoproteins that mediate cell-cell 
adhesion dependent on Ca2+. All have the characteristic extracellular cadherin repeats. The 
classical cadherins type I include epithelial (E) and neuronal (N) cadherin that mediate 
strong cell-cell adhesions, in addition to interactions with the actin cytoskeleton (183;184). 
Anterior pituitary cells have an epithelial phenotype, where appropriate cell-to-cell adhesion 
and polarity are fundamental. Expression of the protein E-cadherin is typical for the 
epithelial cells, providing a physical link to both the adjacent cells and to the intracellular 
cytoskeleton. The extracellular domain of E-cadherin of one cell binds to an E-cadherin 
molecule of an adjacent cell. The intracellular domain of the protein is linked to the actin 
cytoskel			Z	ZY		
-'	- and p120 catenin and EPLIN (epithelial 
protein lost in neoplasm) (183;185-187). 
Regulation of E-cadherin 
The level of E-cadherin in a cell is regulated at several levels. E-cadherin gene expression 
can be directly regulated via promoter hypermethylation, resulting in reduced promoter 
activity. Indirectly, the gene expression can be inhibited by increase in E-cadherin-specific 
Z	Z	@	%'	%'	"	=	$ (184;185). These transcriptional 
inhibitors, particularly Snail, are again regulated by different signalling pathways, such as 
receptor tyrosine kinases like EGFR or TGF-'		 Ras-]>'	'	^		
prostaglandin E2 and others (183;188). Newly synthesized E-cadherin 	=		-
catenin for transport to the cell membrane. When localized to the cell membrane, E-cadherin 
is subject for posttranscriptional regulation like phosphorylation, ubiquitination and 
degradation (183). P120 catenin stabilizes E-cadherin to the cell membrane, and loss of E-
cadherin–p120 binding results in rapid endocytosis of the E-cadherin complex. Once 
internalized, E-cadherin needs to be recycled back to the cell membrane to escape 
degradation (183;184). The cytoplasmic tyrosine kinase Src leads to tyrosine 
phosphorylation of E-cadherin =	-catenin, thereby dissociating the complex, and E-
cadherin is then available for ubiquitination mediated by the Hakai protein resulting in 
degradation (189). Glycogen synthase kinase-		^%>, on the other hand, 
phosphorylates the serine residues of E-cadherin, increasing the binding 		-
catenin.  
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The binding of E-=		-		-catenin in the cytoplasm. In 
=='	^%>	ets the remaining cytoplasmic -catenin for degradation by 
phosphorylating the serine residues. If 	-catenin accumulates in the cytosol, it is 
translocated to the nucleus where -catenin acts as a transcriptional coactivator and 
modulates expression of a large number of genes involved in cell proliferation, migration 
and invasion. In eZ	'	^%>			= and Src inactivated, which 
maintains E-cadherin and -catenin in complex at the cell membrane (183-185;190).  
 
 
Figure 3. A simplified overview over some of the regulating pathways of E-cadherin, Snail and 
EMT. Modified after Guarino M et al (2007) and Gavert N et al (2008) (185;191). 
 
Cleavage of E-cadherin and nuclear translocation 
The extracellular domain of E-cadherin is proteolytically cleaved by matrix 
metalloproteases (MMPs), disrupting the cell-cell adhesion (185). Subsequently, the 
remaining E-cadherin can be cleaved by presenilin-1/-secretase at the transmembrane-
cytoplasm interface, generating a soluble E-cadherin fragment in the cytosol (192). The 
p120 catenin promotes this cleavage, and p120 also mediates nuclear translocation of this 
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fragment (193;194). Using an antibody directed against the intracellular domain of E-
cadherin, this E-cadherin fragment has been found in the nucleus in malignant cells of 
different origins, including the endocrine pancreas (195).  
Epithelial-to-mesenchymal transition 
Epithelial-to-mesenchymal transition (EMT) is a biological process describing the 
morphological and molecular process where epithelial cells lose their characteristics with 
intercellular adhesion and gain mesenchymal properties with increased cell motility. The 
EMT process is required during the embryonic development, both during gastrulation and 
formation of various tissues including the neural crest, and is involved in wound healing. It 
is believed that a reactivation of parts of this embryonic EMT program could underlie the 
mechanism of tumour invasion. For tumours of epithelial origin, loss of adhesion and 
increased cell motility providing the tumour the ability to invade locally is necessary for the 
subsequent development of distant metastases. Other characteristics of EMT, like activation 
of specific signalling pathways, are also often seen in carcinogenesis (185;191). Functional 
loss of E-cadherin is a key molecular change in and a hallmark of EMT (185;188), leading 
to destabilization of the epithelial architecture.  
E-cadherin and EMT in tumours 
Studies of several cancer types have demonstrated that E-cadherin often is lost in malignant 
carcinomas of epithelial origin. Loss of E-cadherin is most pronounced in poorly 
differentiated and invasive tumours, and correlates to tumour grade, metastasis and poor 
prognosis. An increase in the expression of transcriptional repressors of E-cadherin, like 
Snail, has also been demonstrated (196-199).  
 In the pituitary, immunohistochemistry has confirmed a high E-cadherin expression 
in normal pituitary cells (46;200). In pituitary tumours, E-cadherin expression has been 
studied only with immunohistochemistry, where reduced E-cadherin expression has been 
found in a proportion of adenomas (200-204). In GH secreting adenomas, reduced E-
cadherin expression has been demonstrated particularly in sparsely granulated adenomas 
with prominent fibrous bodies (40;45;46;203). In a large percentage of these adenomas, 
hypermethylation of the E-cadherin promoter was present (46;203). 			
correlation to fibrous bodies in the adenomas, it has been suggested that fibrous bodies are 
developed in relationship with the dysfunction of adhesion molecules in these adenomas 
(40). Reduced E-cadherin expression correlated to tumour size and invasiveness in one 
(203), but not in four other studies (45;46;201;204). Nuclear expression of E-cadherin in 
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pituitary adenomas has been analysed in one study, and was present in a large proportion of 
adenomas, particularly in non-functioning adenomas, and in 4 of 10 somatotroph adenomas. 
The nuclear staining correlated to loss of membranous E-cadherin and to tumour 
invasiveness (200).  
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AIMS OF THE STUDIES 
The major aim of our studies was to relate clinical data from patients with acromegaly to 
protein and DNA analyses of the adenoma tissue from these patients. In particular, we 
wanted to explore potential determinants for the variable clinical response to treatment with 
somatostatin analogues.  
The detailed aims for each study were as follows; 
Paper 1: 
 To examine the protein expression of somatostatin receptor 2a in a relatively large 
cohort of somatotroph adenomas 
 To analyse the adenomas with respect to gsp oncogene status 
 To examine if the adenoma expression of SSTR2a and the gsp oncogene status was 
correlated to clinical octreotide efficacy, both the acute and the long-term response 
 To correlate both SSTR2a expression and gsp status to clinical variables like 
preoperative medical treatment, preoperative hormone levels and tumour size and 
invasiveness 
Paper 2: 
 To study the protein level of Raf kinase inhibitory protein (RKIP) in the somatotroph 
pituitary adenomas 
 To examine if the adenoma expression of RKIP was correlated to clinical octreotide 
efficacy, both the acute and the long-term response 
 To correlate the adenoma RKIP expression to preoperative hormone levels, tumour 
size and invasiveness 
 To correlate the RKIP protein level to the adenoma expression of SSTR2a and to the 
presence of gsp oncogene 
Paper 3: 
 To evaluate the protein expression of E-cadherin in a large cohort of somatotroph 
pituitary adenomas, both the protein level (Western blot) and the 
immunohistochemical expression and distribution 
 To examine if E-cadherin nuclear expression is present in somatotroph adenomas 
 To correlate the E-cadherin expression to tumour size and invasiveness 
 To evaluate the protein expression of E-cadherin in relation to acute and long-term 
SMS responses 
 To correlate E-cadherin expression to the expression of SSTR2a and RKIP in the 
adenomas and to gsp oncogene status 
 To evaluate the expression of E-cadherin in relation to preoperative medical 
treatment, and the in vitro response in primary cell cultures to octreotide treatment 
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SUMMARY OF PAPERS 
Paper 1 
The somatostatin analogue octreotide exerts its biological responses through binding to the 
transmembrane somatostatin receptors (SSTR), and reduced expression of SSTR subtype 2 
has been suggested to explain poor octreotide responses in acromegaly. Adenoma SSTR2 
expression had previous been studied only at the mRNA level, and the results comparing 
this to octreotide efficacy had been contradictory. Some studies, but not all, found a better 
somatostatin analogue response in gsp positive adenomas. The objective of this study was to 
determine adenoma SSTR2a protein expression and gsp status in a large group of 
acromegaly patients, and relate this to the clinical effect of octreotide. Seventy-one patients 
were included, and 23 patients had received octreotide treatment prior to transsphenoidal 
surgery. The adenoma SSTR2a expression was examined by immunohistochemistry of 
paraffin sections and Western blot of proteins extracted from frozen adenoma tissue. Gsp 
status was determined by PCR of extracted DNA. An acute octreotide test had been 
performed prior to medical treatment, and the change in IGF-1 level after 6 months 
preoperative octreotide treatment was available in 20 of the preoperatively treated patients.  
The acute octreotide response in non-pretreated patients and the long-term response 
in preoperatively treated patients were significantly better in the adenomas with a large 
proportion of cells with immunohistochemical reactivity for SSTR2a. The SSTR2a protein 
level (Western blot), however, did not correlate with the octreotide response. The 
preoperatively treated group had lower SSTR2a protein level, and there was a tendency 
towards fewer adenomas with a large percentage of positively stained cells in this group. 
Gsp oncogene was detected in 43% of the adenomas, and we found no differences in 
octreotide responses in gsp positive adenomas compared to adenomas without the gsp 
mutation. However, the gsp positive adenomas had higher SSTR2a protein expression (both 
modalities). Neither SSTR2a expression nor gsp status of the adenomas correlated to 
preoperative hormone levels or tumour size. 
To conclude, the clinical effect of octreotide correlates with the proportion of cells 
positive for SSTR2a by immunohistochemical staining, rather than the total protein level in 
the adenoma cells or the gsp status. There may be a downregulation of SSTR2a during 
treatment. 
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Paper 2 
The clinical hormone response to octreotide treatment is highly variable, and has been 
shown to correlate with adenoma protein expression of SSTR2a, a G-protein coupled 
transmembrane receptor. However, in our previous study (paper 1), there were adenomas 
with poor long-term octreotide response despite a high proportion of SSTR2a positive cells. 
Inhibition of the MAP kinase signalling pathway is one of the mechanisms responsible for 
the antiproliferative effects of octreotide. Non-phosphorylated Raf kinase inhibitory protein 
(RKIP) binds to and inhibits Raf1 kinase and thereby reduces MAP kinase signalling, while 
phosphorylated RKIP inhibits G protein receptor internalization and degradation due to 
inhibition of G protein receptor kinase 2. The purpose of this study was to examine RKIP 
protein levels in pituitary somatotroph adenomas, and relate these to clinical characteristics 
and response to octreotide treatment in patients with acromegaly. In 51 patients with active 
acromegaly, the somatotroph adenoma was frozen short time after surgery. The RKIP level 
was analysed by Western blot of proteins extracted from these tumours. An acute 
somatostatin test was performed in 46 of the patients, always prior to SMS treatment. The 
biochemical long-term efficacy of SMS treatment was available in 21 patients with 
measurements of the IGF-1 level before and 6 months after medical treatment, and tumour 
shrinkage during treatment could be evaluated in 16 patients.  
There were no associations between the tumour RKIP level and the patient age, 
baseline hormone levels or tumour size. The RKIP level in the adenomas correlated 
significantly to both the acute and the long-term octreotide responses on serum levels of GH 
and IGF-1, respectively. In multiple regression analyses, both the RKIP level and the 
SSTR2a expression were significant determinants for both the GH reduction in the acute test 
and the IGF-1 reduction after approximately 6 months. No correlation between adenoma 
RKIP level and tumour size reduction during SMS treatment was found, but only 16 patients 
had data available for this analysis. There was no correlation between RKIP level and 
previously analysed SSTR2a protein expression or gsp status.  
In conclusion, in addition to the SSTR2a expression, the adenoma RKIP protein 
level seems to be important for the clinical effect of SMS treatment, where low levels of 
RKIP correlate to poor clinical response to SMS. 
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Paper 3 
Loss of the transmembrane adhesion protein E-cadherin and nuclear translocation of its 
intracellular domain have been associated with poorly differentiated and invasive tumours, 
metastasis and poor prognosis in carcinomas. This has also been demonstrated in a 
proportion of somatotroph pituitary adenomas, correlating to tumour invasiveness in some 
studies. Our objective was to investigate the protein expression of E-cadherin in 
somatotroph adenomas, and relate this to tumour characteristics and to the clinical SMS 
response, and in addition to the previously analysed SSTR2a and RKIP expression. We 
examined the adenoma E-cadherin protein expression by Western blot analysis (61 patients) 
and by immunohistochemistry (80 patients), the latter with antibodies against both 
extracellular and intracellular domains of E-cadherin. Tumour size and invasiveness was 
analysed on MRI scans. An acute octreotide test was performed in 50 patients not 
preoperatively treated with SMS, and reduction of IGF-1 and tumour shrinkage was 
analysed in 26 and 23 patients treated with SMS prior to surgery. Primary cell cultures from 
the adenomas of five patients were cultured with and without octreotide present. 
This study demonstrated that membranous E-cadherin is frequently reduced in 
somatotroph adenomas. Low E-cadherin levels (Western blot) correlated to large adenomas, 
but to tumour invasiveness only in the preoperatively treated group. There was also a 
positive correlation between E-cadherin level and tumour shrinkage following SMS 
pretreatment, and a trend towards positive correlation to IGF-1 reduction. Reduced 
membranous E-cadherin correlated to large and invasive adenomas and to acute octreotide 
response. Nuclear E-cadherin staining was found in 9 patients (11 %), and correlated to 
large tumours and to poor biochemical and tumour response to preoperative SMS treatment. 
Patients treated with SMS prior to surgery had significantly lower E-cadherin level 
compared to not pretreated patients, but no different immunohistochemical E-cadherin 
expression. The in vitro results suggested a downregulation at the mRNA level in non-
treated patients (significant in one of two adenomas), but no additional effect of octreotide 
on E-cadherin in cells from SMS treated patients. There was also a positive correlation 
between E-cadherin expression and the SSTR2a and RKIP expression. 
To conclude, this study demonstrates that E-cadherin is downregulated and 
redistributed in a substantial proportion of somatotroph adenomas, with translocation to the 
nucleus in some adenomas. This was associated with large and invasive tumours and with 
poor clinical SMS efficacy. The reduction of E-cadherin expression may be a marker of 
epithelial dedifferentiation in these adenomas. 
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DISCUSSION 
Methodological considerations 
Patient cohort 
All patients included in our studies had active acromegaly verified by typical symptoms, 
biochemical analyses and a visible pituitary tumour on MRI scans. None had received 
radiation therapy prior to surgery. 
Our studies are cross-sectional, although some of the patients were included in 
prospective studies prior to surgery. From 1996, the intention was to collect adenoma tissue 
during surgery from all patients with acromegaly evaluated at the Section of Endocrinology, 
Rikshospitalet. Adenoma tissue was stored at -70 °C, in addition to the tissue in paraffin 
sections. Unfortunately, tumour tissue was not collected for all patients. Until 2005 there 
was none from Section of Endocrinology to ensure that all somatotroph pituitary adenomas 
were included, and the collection of tissue relied on the neurosurgeon to remember this 
during the surgery. We know that some adenomas operated in the period after the former 
main neurosurgeon retired and until the next was proper established, was not collected. 
Probably also some microadenomas have not been included due to little tumour mass. 
Tumour tissue for the pathological examination and diagnosis had priority. There may 
therefore be a selection bias leading to fewer microadenomas in the study cohort. 
Nevertheless, the study cohort consists of the majority of patients with acromegaly 
diagnostically evaluated and surgically treated at Rikshospitalet in this period. 
Another likely selection bias is the decision to treat patients preoperatively with 
SMS compared to direct surgery. Patients might have been selected for preoperative medical 
treatment because they had a large and invasive adenoma. However, more than half of these 
patients included in our studies received pretreatment as participants in clinical randomized 
studies. This was the case for 15 of 23 patients in study 1, 10 of 15 in study 2 and 15 of 29 
in study 3. There is probably a selection bias for the remaining pretreated patients, being 
most important for the findings in paper 3, as discussed later. 
A main strength of our studies is the large cohort of well characterized patients, 
where none had received radiation therapy that could have influenced the tumour protein 
expression. We also found it important to record all preoperative treatment, to ensure that 
we could analyse the preoperatively treated group separately if the protein expression was 
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significantly different in this group. This was the case for both SSTR2a and E-cadherin. In 
study 1 and 3, we therefore evaluated only preoperative long-term SMS treatment for 
assessment of long-term SMS efficacy.  
 
The acute octreotide test 
In patients not treated with somatostatin analogues (in paper 1 and 3 preoperatively treated), 
we used the response from an acute octreotide stimulation test as a measure of SMS 
response. The clinical usefulness of the acute tests has been debated as different studies 
have diverse conclusions (205-207). One study concluded with a  positive predictive value 
(PPV) of 94 % and a negative predictive value (NPV) of 100 % (206), while another found 
PPV of 82 % and NPV of 50 % (207), both using the same definitions of GH levels. 
However, the interpretation of both studies is complicated by the fact that several patients 
received radiation therapy either prior to or during the study. Nevertheless, since this is the 
only measure of SMS efficacy in these patients, we chose to use the acute suppression test. 
We chose to mainly use the percentage reduction of GH measured between two and 
four hours after the test dose. Following the initiation of the POTA study (Preoperative 
Octreotide Treatment in Acromegaly) in 1999 (4), the procedure was improved with the 
measurement of three pre-octreotide GH values (-60, -30 and 0 minutes) instead of only 
baseline (0 minutes), and then measurements both two, tree and four hours after injection 
compared to only two and four hours after. We have observed that the first pre-test GH 
value is often higher than the next two, probably due to stress reaction during needle 
installation. In addition, the test dose was decreased from 100 μg octreotide subcutaneous to 
50 μg. However, in our opinion this change in test dosage has limited effect, as also shown 
in a previous publication (207). Probably, maximal GH suppression is achieved also with a 
50 μg test dose. 
 
GH and IGF-1 measurements 
The biochemical diagnosis and evaluation of patients with acromegaly is based on the levels 
of GH and IGF-1 in serum. However, measuring levels of these two hormones is not 
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different assays and between different laboratories (208-210). In our studies, GH and IGF-1 
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were measured at the Hormone Laboratory, Aker University Hospital, in eight patients. For 
the rest of the patients, the assays were performed at our hospital (Rikshospitalet).  
For GH, we did not perform renewed analyses, but used the value measured at the 
clinical evaluation. During the years, different immunoassays were used. However, at every 
change of method at Rikshospitalet a cross-calibration was performed and a factor added if 
necessary. In our studies, we used this GH level mainly for correlation to baseline 
characteristics which were minor parts of the studies. In the acute octreotide test, all GH 
analyses were performed at the same laboratory with the same assay, and we used mainly 
the percentage reduction in GH, abrogating the problem.  
For IGF-1, renewed measurements were performed in stored serum samples in one 
run to minimize inter assay variability. This was available in approximately half of the 
patients. The new IGF-1 level proved to correlate well to the previous values (r>0.86). Like 
for GH, these values were used only in minor parts of our study. We focused on the 
reduction in IGF-1 after SMS treatment, and for this evaluation the original IGF-1 value was 
used. As for GH, we used the reduction of IGF-1 instead of absolute value. IGF-1 values 
both prior to and after treatment were analysed at the same laboratory with identical assays 
except for one patient. For this patient, one of the IGF-1 values was adjusted after cross-
calibration of the methods. 
As mentioned, for evaluation of biochemical response to SMS treatment we used 
mainly the reduction in IGF-1 level. This is a good clinical parameter of biochemical 
response. However, it has been demonstrated that octreotide may have additional non-
pituitary effects on the GH-IGF-1 axis (211;212). This could have an influence of our 
results since our objective was to evaluate the adenoma antihormone responses to treatment. 
Yet, this would probably have led to false negative results in our studies of adenoma protein 
expression. 
 
MRI analyses 
Tumour volume and invasiveness were measured retrospectively on MRI scans. I performed 
the measurements under guidance from an experienced neuroradiologist (JKH), always 
blinded for patient identity or clinical data. The first analyses were performed together, 
while later the neuroradiologist was consulted if any question of the adenoma border could 
be raised. However, for most of the patients, the neuroradiologist observed the 
measurements, making sure he agreed. We think it was important that the same person made 
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all measurements to be certain that it was done identically for all patients and for both MRI 
scans for the patients long-time treated with SMS. T1 weighted images were used for the 
analyses. The sagittal view was used for analysis of maximal vertical height and anterior-
posterior length, and the coronal view for measurement of maximal transverse diameter 
(width). In the sagittal plane, the diameters were laid perpendicular to each other. We used 
the formula height x length x width x 0.5 (213) for assessment of the tumour volume, and 
the SIPAP grading system for estimation of tumour invasiveness (214). 
If a scan was not available for re-analysis, tumour characteristics were not registered, 
because we observed that primary measurements were often not done systematic. In this 
way, we ensured that all tumour analyses were done as uniform as possible. 
  
Protein expression analyses (Western blot and immunohistochemistry) 
Previous studies of pituitary tumours have often analysed the adenoma mRNA levels. When 
we started our study, this was the case for all published studies of SSTR2a expression 
related to the clinical SMS efficacy (36;37;118;149-151). However, it is the proteins that 
exert the cellular responses, and the protein expression is often subject to posttranslational 
regulation. Indeed, studies have also demonstrated lack of correlation between SSTR 
mRNA and protein expression (133;146). We therefore aimed to evaluate the protein 
expression of somatotroph adenomas in our studies. 
Western blot  
One method to evaluate protein expression is the Western blot analysis. We 
performed Western blot on proteins extracted from frozen tissue collected during surgery. 
The level of the desired protein was quantified relative to the level of a reference protein, 
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hypothesis that the chosen reference protein or mRNA is not regulated in the adenoma cells. 
This is a possible weakness of these methods, since we can not be certain on that. However, 
we chose reference proteins that are generally used in protein analyses of other tissues and 
in mRNA analyses in studies of pituitary adenomas. Due to technical reasons, we used 
either -actin or GAPDH as reference protein depending of the size of the studied protein. 
In paper 2, we used both -actin and 
-tubulin as reference proteins. The antibody staining 
was visualized by chemiluminescence in a camera using visible light, providing a digital 
image of the membrane. The advantage of this camera is the possibility of setting exact 
exposure time, to ensure identical exposure of all membranes. A digital software was used 
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for measuring signal intensity and size for each band, and allowed for subtraction of 
background signal. We ensured that the exposure time was short enough to avoid saturation 
of signals, which would have led to a lower dynamic range with false low levels for bands 
with strong staining intensity. 
A possible bias is the variation between each run of the Western blots, since only 13 
adenomas could be analysed in one membrane. Due to this, we aimed to treat the 
membranes identically to minimize variation, and we included a reference lane between 
blots to evaluate the variation. In paper 2, where Western blot was the only method of 
protein expression analysis, most adenomas were analysed in more than one blot. The mean 
protein level was used in the analyses. 
]	==		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			t does not display the localization of the 
protein, only the protein level in the extract of frozen tissue. In addition to adenoma tissue, 
there might be contamination of blood and other tissues expressing SSTRs, like endothelium 
and fibrous tissue, in the collected samples. This could have interfered with our results. 
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wild-type nucleotide in electropherograms from gsp positive adenomas, suggesting that the 
tissue samples consisted mainly of adenoma cells. 
One advantage of Western blot analysis is the possibility to ensure specificity of the 
antibody. The extracted proteins are separated by size, and the size of all proteins binding to 
the antibody is visualized. The antibodies used in paper 2 and 3 gave only one stained band 
at the expected protein size. The antibody used in paper 1, however, caused staining of 
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bands were unspecific and due to binding of the secondary antibody.  
Immunohistochemistry 
 Immunohistochemistry, on the other hand, displays the localization of the stained 
protein. It is therefore possible to evaluate the expression only in the pituitary adenoma cells 
and not in neighbouring tissue. In addition, the method allows an evaluation of cellular 
localization of the protein. We included immunohistochemical analyses in paper 1 and 3. 
The evaluation of the cellular localization was particularly significant in paper 3, since both 
preserved membranous and gained nuclear localization of E-cadherin was important to 
register. On the other hand, it is not possible to evaluate the specificity of the antibody using 
immunohistochemistry. Except for the E-cadherin antibody raised against the intracellular 
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domain, we therefore performed these analyses using the same antibody in both 
immunohistochemical and Western blot analyses. 
A disadvantage of the immunohistochemistry method is that the adenomas have to 
be semiquantitatively classified according to immunoreactivity, and qualitatively according 
to localization before comparisons with clinical data can be performed. For the proteins we 
analysed, there were no defined classification systems available. Thus, we had to establish 
our own classification system. The analyses are therefore subjective and based on the 
observer’s judgment. Comparisons between different publications are also difficult, as 
discussed further in the next section. In our studies, the adenoma scoring was performed by 
only a single neuropathologist. In paper 1, however, adenomas difficult to score were also 
examined by a second, independent pathologist. These adenomas were scored identically by 
the independent researchers, both blinded for all clinical data. The classification criteria 
decision was based on both the a priori evaluation on what would be important for the clinical 
behaviour of the adenomas and on the classification criteria used in previous studies, but also 
on the actual staining patterns of the adenomas. The latter was of particular relevance for paper 
3, where the pathologist made a detailed description of the staining pattern for each adenoma 
prior to the final definition of the classification criteria. For instance regarding the E-cadherin 
antibody directed against the intracellular domain, we observed that the majority of adenomas 
displayed strong membranous staining in all cells. Among adenomas with reduced 
membranous staining, some showed nuclear positivity. Importantly, no statistical analyses 
were performed prior to the final definition of classification criteria. 
 
Primary cultures 
We established a method for making primary cell culture of pituitary adenomas. The reason 
for this was that we wanted to be able to perform more mechanistical studies. The original 
objective was to alter the expression of RKIP in the cells and evaluate if this led to altered 
octreotide sensitivity in vitro. However, the attempts to increase RKIP expression using 
expression vector or reduce the expression with siRNA were not successful. To our 
knowledge, there are no publications using these methods on primary pituitary cell cultures. 
This can be due to the fact that the methods to modify protein expression in vitro are most 
efficient on dividing cells; cells from human pituitary adenomas rarely proliferate in vitro.
 We did not perform specific procedures to eliminate fibroblasts from the primary 
cultures. However, the morphology of the cultured cells was relatively homogenous, and the 
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cultures showed two different patterns as previously described (215;216). Most adenomas 
consisted of individual or small groups of rounded cells free floating or only weakly 
attached to the well, similar to the described morphology for densely granulated adenomas. 
One adenoma consisted mainly of spindle shaped cells attached to the well, which has been 
described for sparsely granulated adenomas (215). The cultured cells also produced 
relatively high levels of GH which made dilution of the medium necessary for the GH 
measurements by ELISA. Still, we can not exclude the possibility that the primary cultures 
to some extent were contaminated by fibroblasts. 
 
SSTR2a expression and gsp oncogene (Paper 1) 
In this study, we examined the protein expression of somatostatin receptor 2a in a relatively 
large cohort of somatotroph pituitary adenomas. Immunohistochemistry was performed in 
63 patients and Western blot in 53 patients. To our knowledge, this was one of the first 
studies of SSTR2a protein levels in somatotroph pituitary adenomas, and the first to 
correlate SSTR2a protein expression to clinical long-term response to octreotide treatment.  
We demonstrated that adenomas with a large proportion of SSTR2a positive cells 
responded significantly better to octreotide, both in an acute test and during long-term 
treatment. In not preoperatively treated patients, the SSTR2a immunohistochemical 
expression correlated to the octreotide response in the acute test. In patients treated with 
octreotide prior to surgery, there was a correlation to the percentage IGF-1 reduction after 
approximately 6 months treatment. Adenomas with >75 % SSTR2a positive cells responded 
significantly better to octreotide compared to adenomas with less than 75 % of the cells 
positively stained. This is in accordance with a Japanese study investigating the acute 
octreotide test and SSTR2a immunohistochemistry in 22 patients (152). A more recent study 
found correlation between the SSTR2a immunohistochemical expression and the acute 
octreotide response and the in vitro octreotide response in 20 and 24 patients, respectively. 
They also reported correlation between the SSTR2a positivity and the level of IGF-1 after 6 
months postoperative SMS treatment stratified into three groups (77). However, I could not 
reproduce significance using the given data. These two studies also grouped the adenomas 
after the proportion of positive cells, but used positivity in 50 % of cells as the lower level 
for highly positive adenomas and in 10-20 % of cells as the upper level for negative 
adenomas, while we chose to use 75 and 25 %, respectively. The levels for grouping the 
adenomas are arbitrary, but could influence the results if very few adenomas thereby are 
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assigned to one of the groups. The immunohistochemical grading in our study was 
determined independent of group sizes and prior to all analyses, but showed to provide 
relatively equal groups although most of the somatotroph adenomas displayed high 
proportions of SSTR2a positive cells.  
 Our study demonstrated correlation between the clinical octreotide response 
and the proportion of SSTR2a positive cells in the adenoma, but no correlation to the 
SSTR2a protein level assessed by Western blot. We therefore suggested that the response to 
octreotide treatment may be correlated to the proportion of adenoma cells expressing 
SSTR2a, and to a lesser extent to the total amount of SSTR2a in the adenoma cells. A 
previous study of an octreotide sensitive and a partially sensitive adenoma also found 
correlation between GH reduction in an acute test and the percentage of cells labelled for 
SSTR2 mRNA by in situ hybridization (118). There might be a threshold limit of receptor in 
each cell, where the maximal inhibitory effect of somatostatin is achieved. This could 
explain the lack of correlation to mean level of SSTR2a in the adenomas. Another 
explanation could be that the total protein level may not represent the receptor level in the 
cell membrane available for ligand binding. The Western blot analysis do not discriminate 
between membrane bound SSTR2a and SSTR2a internalized into cytoplasm. This receptor 
is often internalized after ligand binding, but in contrast to for instance SSTR3 which 
undergoes degradation once internalized, SSTR2a is recycled back to the cell membrane 
(142;143). In the immunohistochemical analysis, intracytoplasmic immunoreactivity was 
observed in a relatively large number of adenomas with varying intensity although most 
were weak. Unfortunately, we did not analyse this prior to publication, but our data suggests 
that the pretreated patients significantly more often have adenoma cells with cytoplasmic 
staining for SSTR2 compared to the not preoperatively treated patients. This is in 
accordance with the fact that SSTR2a often is internalized after chronic ligand exposure. In 
our study, cytoplasmic staining was noted, but our chosen grading system did only partly 
discriminate between cytoplasmic and membranous staining. In the case of only weak 
cytoplasmic staining in more than 75 % of the cells, the adenoma was a grade 2 adenoma 
despite the high proportion of stained cells. Since SSTR2a is shown to rapidly recycle back 
to the cell membrane instead of degradation, we thought it was appropriate not to neglect 
the cytoplasmic positivity. However, only in very few cases the cytoplasmic staining was 
strong enough to mask the membranous staining pattern. 
We observed that adenomas from preoperatively treated patients had significantly 
lower SSTR2a protein level assessed by Western blot compared to the direct surgery group. 
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In addition, there was tendency towards a lower proportion of grade 3 adenomas (>75 % of 
positive cells) in the pretreated group. When dividing the study population in two groups; 
adenomas with less than and more than 75 % positive cells, the difference was significant 
(p=0.043). This suggests some degree of downregulation of SSTR2a receptors during 
octreotide treatment. A change in the adenoma SSTR2a expression during treatment might 
also explain the observed discrepancy between the results of the acute and long-term effect 
of octreotide in the pretreated patients, because the acute test was performed prior to 
treatment. Clinical tachyphylaxis would probably not be observed if downregulation of the 
receptor occurs and a new expression pattern is established within weeks of treatment. 
Evaluation of the patient’s final clinical effect of treatment is usually done after a few 
months of treatment. The fact that tachyphylaxis is not a clinical problem in the treatment of 
acromegaly is therefore not necessarily in contrast with our observation. Another 
explanation can be that octreotide treatment leads to a decrease in SSTR2a positive cell 
mass, and hence a relative expansion of tumour cell clones lacking SSTR2a (142). In a 
proportion of somatotroph adenomas, the adenoma cells show heterogeneity in SSTR2a 
expression, both in previous (118;121;217) and in our study. Not in accordance with this 
theory, in one of the few reported patients with tachyphylaxis in acromegaly, re-introduction 
of a somatostatin analogue after short-time withdrawal revealed resensitization to treatment 
(145). 
We demonstrated in this study that the response to octreotide was significantly 
associated with the immunohistochemical proportion of adenoma cells stained positively for 
SSTR2a. Nevertheless, there were both patients with few positive cells and a good response 
especially in the acute octreotide test, and patients with almost no clinical effect of 
octreotide despite a high proportion of positive adenoma cells. This suggests that other 
receptors and mechanisms are involved in determining the clinical efficacy of somatostatin 
analogues in the somatotroph adenomas. As reviewed, octreotide also binds to SSTR5, and 
a single study found correlation between the effect of octreotide and the combined SSTR2 
and 5 mRNA level in the adenoma (37). Unfortunately, our testing of the available SSTR5 
antibody did not give reliable staining of the membranes, and data on SSTR5 protein 
expression could therefore not be presented in this study. The same SSTR5 antibody was 
used in another immunohistochemical study, but no correlation between SSTR5 expression 
and response to an acute octreotide challenge was found (152).  
We detected a gsp mutation in 43 % of the 63 patients, a frequency in accordance 
with most other published studies. In contrast to several previous publications, the gsp 
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positive adenomas in our cohort were not smaller and the proportion of microadenomas was 
comparable to the gsp negative adenomas. However, most of the previous studies had 
included relatively few patients, and not all studies used MRI scans for tumour size 
measurements. Similarly, the by far largest study of acute octreotide response in 100 
patients did not confirm a better octreotide efficacy in gsp positive adenomas found in 
smaller study populations, and none has demonstrated difference in IGF-1 response after 
long-term treatment (29;35;38). In our study of a relatively large group of patients, no 
difference in octreotide response was found, neither for the acute nor the long-term efficacy. 
However, there was a significantly higher proportion of adenomas with low 
immunohistochemical expression of SSTR2a among the gsp positive adenomas. Despite 
this, these tumours did not show a reduced octreotide efficacy. In two of the studies 
demonstrating a better response for gsp positive adenomas in an acute octreotide test, equal 
mRNA levels of SSTR2a were found in these adenomas (36;37). This suggests that other 
mechanisms in addition to SSTR2a are responsible for the effect of octreotide in gsp 
positive adenomas. A potential positive effect of gsp oncogene could have been masked in 
our study by a lower proportion of adenoma cells expressing the SSTR2a protein in the gsp 
positive adenomas.  
 
Raf kinase inhibitory protein (RKIP) (Paper 2) 
This study demonstrated a significant correlation between the protein level of RKIP 
in somatotroph adenomas and the response to octreotide in patients with active acromegaly. 
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patients harbouring tumours with low RKIP levels.  
As discussed, the main factor influencing the efficacy of somatostatin analogue 
treatment in acromegaly is the tumour expression of somatostatin receptors, in particular 
receptor subtype 2. In paper 1, we demonstrated a correlation between octreotide response 
and adenoma SSTR2a expression immunohistochemically, where adenomas with a high 
proportion of SSTR2a positive cells responded significantly better to octreotide treatment. 
Nevertheless, the observed exceptions suggested that additional mechanisms downstream of 
the SSTRs can be involved in determining the clinical effect of somatostatin analogues in 
somatotroph adenomas. In the present study, we found a strong correlation between RKIP 
protein level in the adenoma assessed by Western blot and both acute and long-term clinical 
response to octreotide. However, the RKIP level did not correlate to the SSTR2a protein 
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expression assessed by Western blot analysis or by immunohistochemistry. In the multiple 
regression models, both SSTR2a immunohistochemical grading and the RKIP level were 
significant determinants of the octreotide response. When we looked at the observed 
exceptions, we found that the patients with poor octreotide response despite a high 
proportion of SSTR2a positive cells seemed to have low RKIP levels. Similarly, the patients 
with few SSTR2a positive cells, but relatively good octreotide response, had high RKIP 
levels. This suggested a model where SSTR2a expression is a permissive factor for 
octreotide response in acromegaly, with RKIP as an independent modulator of the efficacy 
of somatostatin analogues.  
Despite the fact that RKIP, in addition to SSTR2a, was a significant determinant of 
SMS efficacy in our multiple regression models, we do not know if RKIP itself is crucial or 
whether RKIP is related to an associating unknown factor responsible for the effects. Yet, 
there are potential mechanisms for RKIP to be of importance for the somatostatin analogue 
effect. First, RKIP inhibits the MEK-ERK signalling pathway, which is also inhibited by 
activation of several SSTR subtypes including 2 and 5 (113;165). Synergistic inhibitory 
effect on the MEK-ERK pathway is therefore a possible mechanism for the association 
between adenoma RKIP levels and the clinical efficacy of octreotide. Second, 
phosphorylation of RKIP by protein kinase C activates RKIP binding to and inhibition of G-
protein coupled receptor kinase 2 (GRK2) (171). Hence, internalization and degradation of 
the somatostatin receptor is reduced. However, there was no correlation between total RKIP 
level and the level of SSTR2a in our study. In our subsequent studies following this 
publication, we sought to examine the relevance of RKIP phosphorylation. We tested an 
antibody against phospho-RKIP thoroughly which seemed to bind specifically to the 
phosphorylated form of the protein. However, Western blot analyses of the level of 
phospho-RKIP in the adenomas revealed correlation to total RKIP, but there were no 
correlations to SSTR2a expression or to the clinical SMS response (unpublished). 
RKIP has previously been found to be important for the responses to medical 
?			=	Z						Z	=	
expressed low levels of RKIP. However, increasing RKIP levels by transfection of an 
expression vector resensitized the cells to drug-induced apoptosis. And in previously drug 
sensitive cell lines, downregulation of RKIP led to resistance to the chemotherapeutic drug 
(182)?	Y'			=			-cell-specific CD20, is used in 
combination with chemotherapy for instance in the treatment of non-Hodgkin’s lymphoma. 
In vitro, both rituximab and a newer, humanized CD20 antibody has been shown to sensitize 
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non-Hodgkin’s lymphoma cell lines to chemotherapeutic drug-induced apoptosis, via 
upregulation of RKIP. There was a concomitant decrease in Snail protein expression 
(218;219)?		=			>-ERK pathway and inhibition of the NF-	
pathway were suggested as possible mechanisms for these drug-sensitizing effects. 
We found no correlation between RKIP level and tumour shrinkage. However, 
available MRI scans for this analysis was limited to 16 patients, wherefore a type II 
statistical error can not be ruled out. As discussed above, several studies have demonstrated 
lack of correlation between biochemical effect and tumour size reduction during long-term 
treatment of acromegaly (99;101;105;106), explained by the different mechanisms involved 
in the antitumour and the antihormone responses of SSTR signalling. It is possible that 
RKIP modulates only the mechanisms responsible for the antihormone response to SMS 
analogues. 
 Studies have demonstrated that RKIP acts as a metastasis suppressor gene in both 
prostate cancer and breast cancer, and both studies suggested increased angiogenesis and 
vascular invasion as possible mechanisms (174;177). In ovarian cancer, an in vitro study 
found that RKIP in addition to inhibition of metastasis also inhibited cell proliferation by 
altering cell cycle progression (178). This is in concordance with the study showing that 
RKIP regulates the mitotic checkpoint (172). In our study of pituitary adenomas, the RKIP 
level did not correlate to tumour size and invasiveness. Despite the often locally invasive 
growth of the somatotroph tumours, this could be due to the general benign nature of these 
adenomas. Nevertheless, our studies are not mechanistic, and only associations can be found 
with this study design.  
 
E-cadherin and EMT (Paper 3) 
In the present study, we examined the protein expression of E-cadherin in the somatotroph 
adenomas. This was done with an anti-E-cadherin antibody directed against the extracellular 
domain of the protein in Western blot analysis and immunohistochemistry. In addition, an 
antibody directed against the intracellular domain was used for immunohistochemical 
analyses to detect internalization and nuclear translocation of the cytoplasmic component of 
the protein after proteolytic cleavage. We demonstrated that the E-cadherin protein 
expression in somatotroph pituitary adenomas is variable, and that a low Western blot E-
cadherin level, lost membranous and gained nuclear localization correlate to large tumours, 
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and partly to tumour invasiveness. The E-cadherin protein expression was also associated 
with the somatostatin analogue response, in particular to tumour shrinkage.  
 Our study confirms the variable expression of E-cadherin in somatotroph pituitary 
adenomas that has been found previously (40;45;46;200;201;203). In our large cohort, we 
found a significant negative correlation between E-cadherin protein expression and tumour 
size and also partly to tumour invasiveness. Large and invasive adenomas seemed to have 
lost their membranous E-cadherin expression. This is in contrast with most previous studies, 
however, these have included several types of pituitary adenomas and the methods for 
evaluation of tumour size and invasiveness have not been similar (45;46;201;204). As 
discussed, loss of E-cadherin is a hallmark of EMT and malignant progression in several 
cancers of epithelial origin. Loss of E-cadherin could be only a marker of EMT, but a causal 
role of E-cadherin in tumour progression has been demonstrated in vivo in a mouse model of 
Z	–cell carcinogenesis (220). It has been suggested that loss of E-cadherin not 
only means loss of epithelial adhesion, but also mediates direct activation of signalling 
pathways to cause invasive phenotypes independent of -catenin (220;221). This is also 
supported by in vitro data from thyroid carcinoma cell lines demonstrating that cell lines 
from anaplastic thyroid carcinomas lack E-cadherin expression, and that re-expression of E-
cadherin in these cells resulted in growth arrest by upregulation of p27 (222). Although the 
somatotroph adenomas are not malignant, their growth are often locally invasive. A role for 
E-cadherin in the growth of these tumours can not be ruled out. Alternatively, a theory could 
be that E-cadherin is lost during progressive growth parallel to, or as a marker of, other 
molecular changes allowing the excessive growth in the large and invasive adenomas. 
 We demonstrated a correlation between adenoma expression of E-cadherin and the 
clinical response to treatment with a somatostatin analogue. The acute SMS response 
correlated to E-cadherin expression analysed by all modalities. For the long-term response, 
the E-cadherin level from Western blot did not correlate significantly to the IGF-1 reduction 
following treatment (p=0.054). The immunohistochemical analyses revealed that adenomas 
with present nuclear E-cadherin staining show a poor long-term SMS response, both 
biochemically and with respect to tumour shrinkage. This correlation to somatostatin 
analogue efficacy can be a result of the observed positive correlation between E-cadherin 
expression and the expression of SSTR2a in the adenoma, since the expression of this 
receptor is important for the clinical efficacy of SMS treatment. A coupling between E-
cadherin and the somatostatin receptor signalling pathway has been suggested previously. 
Ligand binding to SSTR2 has been shown to activate the tyrosine phosphatase SHP-1, 
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which dephosphorylates E-cadherin and restores E-cadherin function (223). In a human 
neuroendocrine cell line, blocking of SSTR signalling decreased the membranous E-
cadherin level and resulted in morphological changes of the cells (224). However, in this 
study we found a reduced E-cadherin protein level in patients preoperatively treated with 
SMS, compared to the non-pretreated patients. This suggests a downregulation of E-
cadherin protein in the adenoma cells following SMS treatment, and is contradictory to what 
would be expected from these in vitro studies. One could suspect that our results could be 
caused by sample selection bias, where the patients were selected for preoperative SMS 
treatment because they had large and invasive adenomas. However, similar result was found 
when we analysed only the patient cohort that had been randomized to preoperatively SMS 
treatment or not in a prospective clinical study (the POTA study) (4). Additionally, our in 
vitro results indicate downregulation at the mRNA level in non-treated patients, whereas we 
found no additional effect of octreotide on E-cadherin in tissue from SMS pretreated 
patients. Indeed, in this cohort we have also documented a decreased SSTR2a expression in 
the preoperatively treated patients (paper 1). There seems to be a parallel regulation of 
SSTR2a and E-cadherin in the adenomas. This could reflect loss of epithelial differentiation 
with loss of the SSTR2a normally expressed in the somatotroph cells. The implication of a 
downregulation of the level of these proteins, yet no alteration of immunohistochemical 
cellular distribution and expression, is unclear. 
 The similar phenomenon of parallel regulation could also be true for E-cadherin and 
RKIP. We demonstrated in paper 2 that the adenoma RKIP protein level was correlated to 
the biochemical response to SMS treatment. The known E-cadherin transcription repressor 
SNAIL has also been shown to inhibit RKIP transcription (225) which could explain the 
observed associations between RKIP and E-cadherin. RKIP inhibits the NF-		
which again leads to reduced SNAIL (173;226). Overexpression of RKIP in a prostate 
cancer cell line reduced SNAIL, increased E-cadherin (both at protein level) and induced an 
epithelial-like phenotype (227).  
 Most previous studies have used antibodies against the extracellular domain of E-
cadherin for protein analyses. In our immunohistochemical analyses, we chose to use both 
this antibody, but in addition an antibody directed against the intracellular domain of the 
protein, because we wanted to study nuclear translocation of E-cadherin. A nuclear 
accumulation of the intracellular domain of E-cadherin has been demonstrated in several 
cancer types (228-230). We found nuclear accumulation of E-cadherin combined with loss 
of membranous E-cadherin in a few adenomas (9/80), but in a lower proportion of 
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adenomas than in a recent published study (200). Compared to this study, which described 
nuclear staining of all intensities, we found weak nuclear positivity in all of these adenomas 
except one with moderate immunoreactivity. The adenomas with nuclear E-cadherin 
positivity can represent a dedifferentiated phenotype of the somatotroph adenomas. They 
had very low E-cadherin protein level assessed by Western blot, they were larger compared 
to the adenomas with membranous positivity in all cells, and they displayed a poor acute 
and long-term SMS response. There was a high degree of concordance between the 
immunohistochemical results using the two different antibodies. However, several 
adenomas showed membranous positivity in all cells using the intracellular domain 
antibody, but had lost membranous E-cadherin using the extracellular domain antibody. 
This discordance could reflect the known cleavage and loss of the extracellular domain by 
MMPs prior to internalization of the protein. The cytoplasmic staining observed exclusively 
with the intracellular domain antibody could also be due to internalization of only the 
intracellular domain of the protein. 
 
General discussion 
The clinical response to treatment with somatostatin analogues in acromegaly is highly 
variable. Previous genetic studies have not found mutations in the gene for SSTR2, but a 
point mutation on the SSTR5 gene was found in one octreotide resistant patient (231). 
Moreover, known polymorphisms in the receptors SSTR2 and 5 were not associated to SMS 
responsiveness (232). Other studies have indicated that densely granulated adenomas 
respond better to octreotide treatment compared to sparsely granulated adenomas (43;44), 
and that gsp positive adenomas display a better GH response during long-term octreotide 
treatment (29;38). In our studies, we analysed the gsp status of the adenomas. However, our 
main objective was to examine proteins involved in the SMS response, in order to examine 
factors behind the variability in SMS efficacy. We confirmed, as expected, that the protein 
expression of somatostatin receptor 2a in the somatotroph adenoma was of importance for 
the clinical efficacy of SMS treatment. However, we demonstrated patients in our cohort 
with a poor SMS response despite high SSTR2a expression, and vice versa. This led us to 
the hypothesis that mechanisms downstream of the receptor might modify the receptor 
response. Due to the published studies of RKIP in cancers discussing its modulating effect 
on the MAPK pathway and its role in chemotherapeutic sensitivity, this protein could be of 
interest. And, indeed, our study showed that the protein expression of RKIP in the adenomas 
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was a marker of biochemical SMS response, in addition to the SSTR2a expression. The lack 
of associations between SSTR2a expression and total RKIP or phospho-RKIP suggest that 
RKIP does not regulate the SMS response through regulation of GRK2 and internalization 
and degradation of SSTR2a, at least not in the somatotroph cells. Modulation of the MAPK 
pathway resulting in synergistic inhibition of this signalling system by SSTR2a activation 
and RKIP action is probably more likely. As discussed, this pathway is considered a 
probable mechanism for RKIP’s drug-sensitizing effects, in addition to inhibition of the NF-
	Z	(182;218;219). With respect to NF-'		=	 a murine fibroblast cell line 
=		%%$		=				
	==	ZZ		
activation of NF-	(139). In the rat somatotroph cell line GH3, inhibition of NF-	=		
decreased cell viability (233). However, despite the fact that active NF-			
suppress apoptosis, the signalling system can promote cell death in response to certain 
death-inducing signals and in certain cell types (234). The contradictory effect on NF-		
the referred studies can therefore be explained by the different species and cell types 
studied. For the SMS response, inhibition of both the MAPK and NF-	Z		
mainly been considered as mechanisms for the antitumour effect and not the antisecretory 
response (113;122). Thus, the regulatory pathways responsible for the association of RKIP 
to the acute SMS response are therefore unknown. Further studies of RKIP in somatotroph 
adenomas are necessary to evaluate if the expression of RKIP is causal for good SMS 
response or whether RKIP is related to an associating, so far unidentified factor responsible 
for the effects. The multiple regression analysis only identifies RKIP as a marker 
independent of SSTR2a. A natural first approach would be to alter the RKIP expression in 
somatotroph cells in vitro and examine the SMS response. 
 The studies concluding with upregulation of RKIP as a mechanism for the drug 
sensitizing effect of rituximab in non-Hodgkin’s lymphoma also demonstrated a 
concomitant downregulation of the transcription repressor Snail (218;219). Snail is known 
to be a strong repressor of E-cadherin and an inducer of the EMT process (185), see figure 3 
(p. 26). In addition, after demonstrating that E-cadherin and RKIP was coexpressed in 
several cancer cell lines and that RKIP was negatively correlated to Snail in metastatic 
Z		'				==		%			>~	YZ	
(225). Activated NF-			YZ		%	(235). Snail has been coupled to 
resistance to chemotherapeutic drugs both in melanoma cells, pancreatic cancer and lung 
adenocarcinoma cells (236-238). It has been suggested that a regulatory NF--Snail-RKIP 
circuitry is established in cancer cells, maintaining a drug resistant phenotype (239). Despite 
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the benign nature of the somatotroph adenomas, we hypothesized that these mechanisms 
may be present in the somatotroph pituitary adenomas, particularly in the SMS resistant 
tumours. We therefore wanted to analyse the protein expression of Snail and E-cadherin in 
the adenomas. However, testing of two different anti-Snail antibodies did not give reliable 
staining of the Western blot membrane. The E-cadherin antibody, on the other hand, was 
specific. Consequently, only the E-cadherin expression could be evaluated in this study. Our 
finding of a positive correlation between E-cadherin and RKIP is in concordance with a 
previous publication (225). Adenoma E-cadherin expression correlated positively to 
biochemical SMS response, but also to tumour shrinkage following SMS treatment. It 
would have been of interest to analyse whether E-cadherin was an independent predictor of 
SMS response. However, a multiple regression analysis could not be performed due to the 
high correlation between the included variables. The E-cadherin protein expression also 
showed a strong correlation to the SSTR2a protein expression in the adenomas. 
 As reviewed, activation of SSTR2 leads to activation of the tyrosine phosphatase 
SHP-1, an important step for several downstream pathways in SSTR2 signalling (129;138). 
This PTP dephosphorylates E-cadherin at tyrosine residues, which stabilizes and restores E-
cadherin function, while tyrosine phosphorylation leads to degradation (189;223). An in 
vitro study of pancreatic cancer cells demonstrated that SSTR2 positive cells had reduced 
tyrosine phosphorylation of E-cadherin, yet unchanged E-cadherin protein level. Moreover, 
an allograft of these cells displayed reduced invasiveness after SMS treatment compared to 
cells not expressing SSTR2  (223). Another study of a neuroendocrine tumour cell line 
showed that octreotide treated cells had high membranous E-cadherin immunoreactivity, 
while treatment with SSTR2 blocking antibodies was followed by reduced E-cadherin and 
morphological changes referred to as neuroendocrine-to-mesenchymal transition (NMT) 
(224). These studies show that there are several possible mechanisms for interplay between 
the regulation of SSTR2 and E-cadherin. However, they do not support our results of E-
cadherin downregulation during SMS treatment and SSTR2 activation. Our studies were 
designed to show associations and not mechanisms. Yet, our small in vitro study of primary 
cultured adenoma cells supported our results of reduced E-cadherin protein levels in 
adenomas from preoperatively SMS treated patients. On the other hand, in our cohort there 
was also a reduced protein expression of SSTR2a in the pretreated patients. In the future, the 
in vitro E-cadherin response to octreotide stimulation should be studied in a larger group of 
adenomas, with correlation to SSTR2a protein level of these cells and their secretory GH 
response. This could clarify if regulation of E-cadherin during octreotide treatment is 
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universal or restricted to a subgroup of adenomas, for instance the octreotide resistant 
adenoma cells. 
 TGF- 									@		=	s, 
and that the SSTR pathway is a determinant for this response. Any disruption in the 
activation of TGF- 		%%'	=		=	@		%%			
antibodies, led to NMT (224). In addition, it has been demonstrated that TGF-	=	
EMT in breast cancer cells via activation of NF- (240), but also via increase in 
cyclooxygenase-2 (Cox-2) and prostaglandin E2 (PGE2). Stimulation with TGF-	=		
increased Cox-2 expression which again stimulated PGE2 production (241). In non-small 
cell lung cancer, activation of Cox-2-dependent pathways was followed by decreased E-
cadherin. In vitro treatment with the Cox-2 inhibitor celecoxib increased E-cadherin 
expression, while treatment of these cells with PGE2 decreased E-cadherin via modulation 
of the transcriptional Z	%	=	-1 (242). Studies of gastric cancers have 
demonstrated increased apoptosis with a combination treatment of octreotide and a Cox-2 
inhibitor (243;244). The tumour expression of SSTR2 mRNA was also higher in the 
celecoxib treated adenomas compared to the not treated patients (243). In patients with 
gastric cancer randomized to direct surgery or to pretreatment with celecoxib, the tumours 
of the latter group displayed increased expression of E-cadherin assessed by 
immunohistochemistry and increased apoptotic index (245). This leads to the hypothesis 
that inhibition of Cox-2 results in reversibility of an EMT process, with a concomitant 
increase in the expression of SSTR2. Cox-2 is usually not expressed in normal tissue, but is 
frequently overexpressed in neoplasms including pituitary adenomas (246). Future studies 
of this pathway can therefore be of interest. 
There have been several reports on agents regulating some of the above mentioned 
mechanisms for the EMT process and drug resistance. Proteasome inhibitors and nitric 
oxide donating agents have been shown to inhibit the NF--Snail-RKIP circuitry, 
suppressing EMT and increasing chemotherapy sensitivity (226;227;247;248). As 
mentioned, rituximab leads to drug sensitization through upregulation of RKIP. However, in 
the treatment of acromegaly, the acceptance of drug side effects will be lower than in the 
treatment of an invasive and metastasizing cancer.  
Our results of reduced E-cadherin expression in a proportion of adenomas and the 
correlation to large and invasive tumours and poor response to somatostatin treatment, may 
reflect an EMT-like process and dedifferentiation in these tumours. The correlation of E-
cadherin and SSTR2a expression suggests a simultaneous loss of SSTR2a during this 
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process. It is particularly this group of acromegaly patients that hopefully can benefit from 
future studies on modulators of the EMT process and potentially drug sensitizing agents in 
pituitary adenomas. 
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CONCLUSION 
To conclude, our studies demonstrated that; 
 The somatostatin receptor subtype 2a was downregulated at the protein level in a 
substantial proportion of somatotroph adenomas, and this was associated with 
reduced biochemical response to SMS treatment in the patients with acromegaly. 
 There was no difference in octreotide responsiveness in gsp positive compared to 
gsp negative adenomas. 
 The protein level of Raf kinase inhibitory protein (RKIP) in the somatotroph 
adenomas was correlated to the biochemical response to somatostatin analogue 
treatment, where a low RKIP level was associated with poor SMS efficacy. The 
RKIP level did not correlate to SSTR2a protein expression of the adenomas. This 
suggests RKIP as a modulator of the signalling downstream of SSTR binding. 
 Reduced E-cadherin protein level and reduced membranous localization of E-
cadherin were apparent in a subgroup of GH producing pituitary adenomas, and 
some of these adenomas also displayed nuclear translocation of the intracellular 
domain of the protein. This correlated to large and invasive adenomas, and to poor 
biochemical SMS response and little tumour shrinkage following treatment. 
 Reduced E-cadherin protein expression was associated with reduced protein 
expression of SSTR2a and RKIP, and may be a marker of epithelial dedifferentiation 
and an EMT-like process in these adenomas 
 
  
53 
 
REFERENCES 
 1.  Guillemin R 2006 Acromegaly, day one and now, 120 years later. Neuroendocrinology 
83:136-138 
 2.  Sheaves R 1999 A history of acromegaly. Pituitary 2:7-28 
 3.  Melmed S 2006 Medical progress: Acromegaly. N Engl J Med 355:2558-2573 
 4.  Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, 
Cooper JG, Hald JK, Fougner SL, Bollerslev J 2008 Preoperative octreotide treatment in 
newly diagnosed acromegalic patients with macroadenomas increases cure short-term 
postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984-2990 
 5.  Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D 2007 
]--									-			"	
acromegalic subjects. Eur J Endocrinol 157:399-409 
 6.  Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen 
H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, 
Stenman UH, Viikari J, Voutilainen E 2005 A nationwide survey of mortality in 
acromegaly. J Clin Endocrinol Metab 90:4081-4086 
 7.  Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, 
Halperin I, Lucas-Morante T, Moreno B, Obiols G, de PP, Paramo C, Pico A, Torres 
E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M 2004 Epidemiology, 
clinical characteristics, outcome, morbidity and mortality in acromegaly based on the 
Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 
151:439-446 
 8.  Petersenn S, Buchfelder M, Gerbert B, Franz H, Quabbe HJ, Schulte HM, 
Grussendorf M, Reincke M 2009 Age and sex as predictors of biochemical activity in 
acromegaly: analysis of 1485 patients from the German Acromegaly Register. Clin 
Endocrinol (Oxf) 71:400-405 
 9.  Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A 2006 High 
prevalence of pituitary adenomas: a cross-	=			Z		&'	?	
J Clin Endocrinol Metab 91:4769-4775 
 10.  Fernandez A, Karavitaki N, Wass JA 2009 Prevalence of pituitary adenomas: a 
community-based, cross-	=			*Y='	>?	X	=	
(Oxf) 
 11.  Reid TJ, Post KD, Bruce JN, Nabi KM, Reyes-Vidal CM, Freda PU 2009 Features at 
diagnosis of 324 patients with acromegaly did not change from 1981 to 2006; Acromegaly 
remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 
 12.  Danzig J $__`	]?	+	|$-825 
 13.  Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of 
acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152 
 14.  FOUGNER K, JENSEN V 1955 [Acromegaly with severe osteoarticular changes; case 
report.]. Tidsskr Nor Laegeforen 75:742-744 
 15.  Sievers C, Dimopoulou C, Pfister H, Lieb R, Steffin B, Roemmler J, Schopohl J, 
Mueller M, Schneider HJ, Ising M, Wittchen HU, Stalla GK 2009 Prevalence of mental 
disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol 
(Oxf) 71:691-701 
 16.  Asa SL, Ezzat S 2002 The pathogenesis of pituitary tumours. Nat Rev Cancer 2:836-849 
 17.  Heaney AP, Melmed S 2004 Molecular targets in pituitary tumours. Nat Rev Cancer 4:285-
295 
 18.  Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S 1990 Clonal origin of pituitary 
adenomas. J Clin Endocrinol Metab 71:1427-1433 
 19.  Grossman AB 2009 The molecular biology of pituitary tumors: a personal perspective. 
Pituitary 12:265-270 
 20.  Tichomirowa MA, Daly AF, Beckers A 2009 Familial pituitary adenomas. J Intern Med 
266:5-18 
54 
 
 21.  Cazabat L, Guillaud-Bataille M, Bertherat J, Raffin-Sanson ML 2009 Mutations of the 
gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm Res 
71:132-141 
 22.  Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA 2000 
Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-
11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin 
Endocrinol Metab 85:707-714 
 23.  Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen 
K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De ME, Makinen MJ, Launonen 
V, Karhu A, Aaltonen LA 2006 Pituitary adenoma predisposition caused by germline 
mutations in the AIP gene. Science 312:1228-1230 
 24.  Leontiou CA, Gueorguiev M, van der SJ, Quinton R, Lolli F, Hassan S, Chahal HS, 
Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, 
Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A, Jr., Gadelha MR, Monson JP, 
Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, 
Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, 
Korbonits M 2008 The role of the aryl hydrocarbon receptor-interacting protein gene in 
familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93:2390-2401 
 25.  Khoo SK, Pendek R, Nickolov R, Luccio-Camelo DC, Newton TL, Massie A, Petillo D, 
Menon J, Cameron D, Teh BT, Chan SP 2009 Genome-wide scan identifies novel 
modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. Endocr 
Relat Cancer 16:1057-1063 
 26.  Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L 1989 GTPase 
inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human 
pituitary tumours. Nature 340:692-696 
 27.  Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark 
OH, Kawasaki E, Bourne HR, . 1990 Two G protein oncogenes in human endocrine 
tumors. Science 249:655-659 
 28.  Vallar L, Spada A, Giannattasio G 1987 Altered Gs and adenylate cyclase activity in 
human GH-secreting pituitary adenomas. Nature 330:566-568 
 29.  Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, 
Enjalbert A, Jaquet P 1998 Pronostic and therapeutic consequences of Gs alpha mutations 
in somatotroph adenomas. J Clin Endocrinol Metab 83:1604-1610 
 30.  Kim HJ, Kim MS, Park YJ, Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, 
Jung HW, Han DH, Lee HS, Chi JG 2001 Prevalence of Gs alpha mutations in Korean 
patients with pituitary adenomas. J Endocrinol 168:221-226 
 31.  Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR 1990 Clinical 
characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J 
Clin Endocrinol Metab 71:1416-1420 
 32.  Yang I, Park S, Ryu M, Woo J, Kim S, Kim J, Kim Y, Choi Y 1996 Characteristics of 
gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur 
J Endocrinol 134:720-726 
 33.  Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G 1990 
Clinical, biochemical, and morphological correlates in patients bearing growth hormone-
secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin 
Endocrinol Metab 71:1421-1426 
 34.  Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R 1993 
Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and 
gsp-negative pituitary tumors. Neurosurgery 33:198-203 
 35.  Yasufuku-Takano J, Takano K, Morita K, Takakura K, Teramoto A, Fujita T 2006 
Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ 
geographically or racially? Prevalence of gsp mutations in Japanese patients revisited. Clin 
Endocrinol (Oxf) 64:91-96 
 36.  Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A 1999 
Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and 
55 
 
somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide 
sensitivity. J Clin Endocrinol Metab 84:2759-2765 
 37.  Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, 
Park S 2004 Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth 
hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and 
response to octreotide. Endocr J 51:227-236 
 38.  Mendoza V, Sosa E, Espinosa-de-Los-Monteros AL, Salcedo M, Guinto G, Cheng S, 
Sandoval C, Mercado M 2005 GSPalpha mutations in Mexican patients with acromegaly: 
potential impact on long term prognosis. Growth Horm IGF Res 15:28-32 
 39.  Horvath E, Kovacs K 2006 Pathology of acromegaly. Neuroendocrinology 83:161-165 
 40.  Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur 
RM, Yamada S 2008 Clinicopathological features of growth hormone-producing pituitary 
adenomas: difference among various types defined by cytokeratin distribution pattern 
including a transitional form. Endocr Pathol 19:82-91 
 41.  Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K 1993 Growth 
hormone-producing pituitary adenomas: correlations between clinical characteristics and 
morphology. Neurosurgery 33:20-27 
 42.  Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, 
Frank SJ, Ezzat S 2007 A growth hormone receptor mutation impairs growth hormone 
autofeedback signaling in pituitary tumors. Cancer Res 67:7505-7511 
 43.  Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S 2005 The implication of somatotroph 
adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol 
Metab 90:6290-6295 
 44.  Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K 1995 In 
vivo responsiveness of morphological variants of growth hormone-producing pituitary 
adenomas to octreotide. Eur J Endocrinol 133:686-690 
 45.  Nishioka H, Haraoka J, Akada K 2003 Fibrous bodies are associated with lower GH 
production and decreased expression of E-cadherin in GH-producing pituitary adenomas. 
Clin Endocrinol (Oxf) 59:768-772 
 46.  Xu B, Sano T, Yoshimoto K, Yamada S 2002 Downregulation of E-cadherin and its 
undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous 
bodies. Endocr Pathol 13:341-351 
 47.  Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, 
Jenkins PJ, Monson JP, Besser GM, Lowe DG, Grossman AB 1999 Low expression of 
the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and 
malignant pituitary tumors. J Clin Endocrinol Metab 84:3823-3830 
 48.  Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, 
Farrell WE, Claret FX, Grossman AB 2002 Expression of phosphorylated p27(Kip1) 
protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin 
Endocrinol Metab 87:2635-2643 
 49.  Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF, Jr., Lloyd 
RV 1997 Transforming growth factor-beta, transforming growth factor-beta receptor II, and 
p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509-
519 
 50.  Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni 
MR, Khalaf S, Jordan S, Czirjak S, Hanzely Z, Nagy GM, Goth MI, Grossman AB, 
Korbonits M 2006 Somatostatin analogues stimulate p27 expression and inhibit the MAP 
kinase pathway in pituitary tumours. Eur J Endocrinol 155:371-379 
 51.  LeRiche VK, Asa SL, Ezzat S 1996 Epidermal growth factor and its receptor (EGF-R) in 
human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol 
Metab 81:656-662 
 52.  Onguru O, Scheithauer BW, Kovacs K, Vidal S, Jin L, Zhang S, Ruebel KH, Lloyd RV 
2004 Analysis of epidermal growth factor receptor and activated epidermal growth factor 
receptor expression in pituitary adenomas and carcinomas. Mod Pathol 17:772-780 
56 
 
 53.  Abbass SA, Asa SL, Ezzat S 1997 Altered expression of fibroblast growth factor receptors 
in human pituitary adenomas. J Clin Endocrinol Metab 82:1160-1166 
 54.  Morita K, Takano K, Yasufuku-Takano J, Yamada S, Teramoto A, Takei M, Osamura 
RY, Sano T, Fujita T 2008 Expression of pituitary tumour-derived, N-terminally truncated 
isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour 
invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting 
pituitary adenomas. Clin Endocrinol (Oxf) 68:435-441 
 55.  Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, 
Kovacs K, Ezzat S 2004 Cytoplasmic expression of fibroblast growth factor receptor-4 in 
human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J 
Clin Endocrinol Metab 89:1904-1911 
 56.  Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP 2008 
Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61-67 
 57.  Holdaway IM, Bolland MJ, Gamble GD 2008 A meta-analysis of the effect of lowering 
serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95 
 58.  Kauppinen-Makelin R, Sane T, Valimaki MJ, Markkanen H, Niskanen L, Ebeling T, 
Jaatinen P, Juonala M, Pukkala E 2009 Increased cancer incidence in acromegaly - a 
nationwide survey. Clin Endocrinol (Oxf) 
 59.  Couldwell WT 2004 Transsphenoidal and transcranial surgery for pituitary adenomas. J 
Neurooncol 69:237-256 
 60.  Laws ER 2008 Surgery for acromegaly: evolution of the techniques and outcomes. Rev 
Endocr Metab Disord 9:67-70 
 61.  Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, 
Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A 2009 Guidelines for 
acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517 
 62.  Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients 
wi							?		+	=	"|$`-387 
 63.  Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after 
transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91 
 64.  Bates PR, Carson MN, Trainer PJ, Wass JA 2008 Wide variation in surgical outcomes 
for acromegaly in the UK. Clin Endocrinol (Oxf) 68:136-142 
 65.  Clayton RN 1999 How many surgeons to operate on acromegalic patients? Clin Endocrinol 
(Oxf) 50:557-559 
 66.  Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM 1999 Outcome of surgery for 
acromegaly--the experience of a dedicated pituitary surgeon. QJM 92:741-745 
 67.  Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth 
hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I 
concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol 
Metab 89:1613-1617 
 68.  Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins 
MM, Bates AS, Stewart PM 2009 ACTH Deficiency, Higher Doses of Hydrocortisone 
Replacement, and Radiotherapy Are Independent Predictors of Mortality in Patients with 
Acromegaly. J Clin Endocrinol Metab 94:4216-4223 
 69.  Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Silvestrini F 1972 Inhibitory effect of 
L-Dopa on GH release in acromegalic patients. J Clin Endocrinol Metab 35:941-943 
 70.  Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F 1974 
Decreased plasma growth hormone (GH) levels i			X	"|$--
alpha ergocryptine) administration. J Clin Endocrinol Metab 38:910-912 
 71.  Moyes VJ, Metcalfe KA, Drake WM 2008 Clinical use of cabergoline as primary and 
adjunctive treatment for acromegaly. Eur J Endocrinol 159:541-545 
 72.  Abs R, Verhelst J, Maiter D, Van AK, Nobels F, Coolens JL, Mahler C, Beckers A 
1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol 
Metab 83:374-378 
 73.  Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, 
Holder G, Sheppard MC, Bates A, Stewart PM 2009 Medical therapy in patients with 
57 
 
acromegaly: predictors of response and comparison of efficacy of dopamine agonists and 
somatostatin analogues. J Clin Endocrinol Metab 94:1255-1263 
 74.  Cozzi R, Attanasio R, Lodrini S, Lasio G 2004 Cabergoline addition to depot somatostatin 
analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin 
status. Clin Endocrinol (Oxf) 61:209-215 
 75.  Jallad RS, Bronstein MD 2009 Optimizing medical therapy of acromegaly: beneficial 
effects of cabergoline in patients uncontrolled with long-acting release octreotide. 
Neuroendocrinology 90:82-92 
 76.  Marzullo P, Ferone D, Di SC, Pivonello R, Filippella M, Lombardi G, Colao A 1999 
Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant 
acromegalic patients. Pituitary 1:115-120 
 77.  Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, 
Minuto F, Colao A, Lamberts SW, Hofland LJ 2008 Correlation of in vitro and in vivo 
somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with 
immunohistochemical evaluation of somatostatin and dopamine receptors and electron 
microscopy. J Clin Endocrinol Metab 93:1412-1417 
 78.  Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA 1991 
Dimerization of the extracellular domain of the human growth hormone receptor by a single 
hormone molecule. Science 254:821-825 
 79.  Chen WY, Wight DC, Chen NY, Coleman TA, Wagner TE, Kopchick JJ 1991 
Mutations in the third alpha-helix of bovine growth hormone dramatically affect its 
	=			=					?	+		X	
266:2252-2258 
 80.  Chen WY, Wight DC, Wagner TE, Kopchick JJ 1990 Expression of a mutated bovine 
growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci U S A 
87:5061-5065 
 81.  Cunningham BC, Jhurani P, Ng P, Wells JA 1989 Receptor and antibody epitopes in 
human growth hormone identified by homolog-scanning mutagenesis. Science 243:1330-
1336 
 82.  Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor 
antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 
23:623-646 
 83.  Chen WY, Wight DC, Mehta BV, Wagner TE, Kopchick JJ 1991 Glycine 119 of bovine 
growth hormone is critical for growth-promoting activity. Mol Endocrinol 5:1845-1852 
 84.  Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brubach K, Stalla G, 
Strasburger C 2009 The German ACROSTUDY: Past and Present. Eur J Endocrinol 
 85.  Hodish I, Barkan A 2008 Long-term effects of pegvisomant in patients with acromegaly. 
Nat Clin Pract Endocrinol Metab 4:324-332 
 86.  Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, 
Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner 
MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, 
Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, 
Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett 
WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist 
pegvisomant. N Engl J Med 342:1171-1177 
 87.  Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ 2009 A randomized, 
controlled, multicentre trial comparing pegvisomant alone with combination therapy of 
pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 
71:549-557 
 88.  van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, 
Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend 
KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, 
Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of 
acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-
1759 
58 
 
 89.  Neggers SJ, van der Lely AJ 2009 Somatostatin analog and pegvisomant combination 
therapy for acromegaly. Nat Rev Endocrinol 5:546-552 
 90.  Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, 
Orskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth 
hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631 
 91.  Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R 1973 
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth 
hormone. Science 179:77-79 
 92.  Siler TM, VandenBerg G, Yen SS, Brazeau P, Vale W, Guillemin R 1973 Inhibition of 
growth hormone release in humans by somatostatin. J Clin Endocrinol Metab 37:632-634 
 93.  Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Kastin AJ, McNeilly 
AS, Mortimer CH, Phenekos C, Tunbridge WM, Weightman D 1973 Action of growth-
hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet 2:581-584 
 94.  Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless 
1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with 
prolonged action. Life Sci 31:1133-1140 
 95.  Plewe G, Beyer J, Krause U, Neufeld M, del PE 1984 Long-acting and selective 
suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in 
acromegaly. Lancet 2:782-784 
 96.  Lamberts SW, Oosterom R, Neufeld M, del PE 1985 The somatostatin analog SMS 201-
995 induces long-acting inhibition of growth hormone secretion without rebound 
hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161-1165 
 97.  Ch'ng LJ, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR 1985 Long 
										?		=	+	X	
Res Ed) 290:284-285 
 98.  Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, 
van der Lely AJ 2009 Medical therapy of acromegaly: efficacy and safety of somatostatin 
analogues. Drugs 69:2207-2226 
 99.  Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, 
McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass 
JA, Wardlaw JM 2002 Primary medical therapy for acromegaly: an open, prospective, 
multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide 
on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 
87:4554-4563 
 100.  Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, 
Petersenn S, Podoba J, Safari M, Wardlaw J 2007 A prospective, multicentre study to 
investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable 
octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 
66:859-868 
 101.  Luque-Ramirez M, Portoles GR, Varela C, Albero R, Halperin I, Moreiro J, Soto A, 
Casamitjana R 2009 The Efficacy of Octreotide LAR as Firstline Therapy for Patients with 
Newly Diagnosed Acromegaly is Independent of Tumor Extension: Predictive Factors of 
	=		Z?	<		 
 102.  Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, 
Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC 2009 Octreotide LAR 
vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, 
multicentre study. Clin Endocrinol (Oxf) 70:757-768 
 103.  Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew 
D, Kleinberg D, Barkan A 2005 A critical analysis of pituitary tumor shrinkage during 
primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410 
 104.  Bevan JS 2005 Clinical review: The antitumoral effects of somatostatin analog therapy in 
acromegaly. J Clin Endocrinol Metab 90:1856-1863 
 105.  Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, 
Caron P 2007 Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour 
59 
 
size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting 
pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67:282-289 
 106.  Lundin P, Eden EB, Karlsson FA, Burman P 1997 Long-term octreotide therapy in 
growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am J 
Neuroradiol 18:765-772 
 107.  Schonbrunn A, Tashjian H, Jr. 1978 Characterization of functional receptors for 
so			Z			?	+		X	$|`-6483 
 108.  Srikant CB, Patel YC 1981 Receptor binding of somatostatin-28 is tissue specific. Nature 
294:259-260 
 109.  Tran VT, Beal MF, Martin JB 1985 Two types of somatostatin receptors differentiated by 
cyclic somatostatin analogs. Science 228:492-495 
 110.  Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S 1992 Cloning and functional 
characterization of a family of human and mouse somatostatin receptors expressed in brain, 
gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 89:251-255 
 111.  Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell 
GI, Seino S 1992 Somatostatin receptors, an expanding gene family: cloning and functional 
characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 
6:2136-2142 
 112.  Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, 
Imura H, Seino S, . 1993 Cloning, functional expression and pharmacological 
characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor 
Z?		Z		X	"|-852 
 113.  Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198 
 114.  Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C 2008 Antitumor effects of 
somatostatin. Mol Cell Endocrinol 286:230-237 
 115.  Vanetti M, Vogt G, Hollt V 1993 The two isoforms of the mouse somatostatin receptor 
%%$]	=	%%$	=iffer in coupling efficiency to adenylate cyclase and in 
agonist-==	Z	=?	%	&	"$_-266 
 116.  Cole SL, Schindler M 2000 Characterisation of somatostatin sst2 receptor splice variants. J 
Physiol Paris 94:217-237 
 117.  Panetta R, Patel YC 1995 Expression of mRNA for all five human somatostatin receptors 
(hSSTR1-5) in pituitary tumors. Life Sci 56:333-342 
 118.  Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, 
Enjalbert A, Ouafik LH 2000 Human somatostatin receptor subtypes in acromegaly: 
distinct patterns of messenger ribonucleic acid expression and hormone suppression identify 
different tumoral phenotypes. J Clin Endocrinol Metab 85:781-792 
 119.  Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A 1995 
Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol 
Metab 80:1386-1392 
 120.  Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H 2005 Systemic 
distribution of somatostatin receptor subtypes in human: an immunohistochemical study. 
Endocr J 52:605-611 
 121.  Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M 2006 Mapping of somatostatin 
receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 59:274-279 
 122.  Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in 
somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 
2:999-1017 
 123.  Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A 2001 
Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone 
secretion in human somatotroph tumors. J Clin Endocrinol Metab 86:2976-2981 
 124.  Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C 
2004 Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 1014:121-131 
 125.  Cohen AB, Lessell S 2009 Angiogenesis and pituitary tumors. Semin Ophthalmol 24:185-
189 
60 
 
 126.  Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, 
Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De ML, Maira G, gli Uberti EC 
2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in 
non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor 
secretion. Endocr Relat Cancer 14:91-102 
 127.  Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL 2005 Somatostatin receptors 2 
=	|		Z	YZ=		Z	=?		+	X	$"-1498 
 128.  Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, 
Noonan DM, Schettini G, Albini A 2003 Somatostatin inhibits tumor angiogenesis and 
growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase 
and mitogen-activated protein kinase activities. Endocrinology 144:1574-1584 
 129.  Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Theveniau M, Nahmias C, 
Vaysse N, Susini C 1997 The tyrosine phosphatase SHP-1 associates with the sst2 
somatostatin receptor and is an essential component of sst2-mediated inhibitory growth 
?	+		X	$`$$-24454 
 130.  Ferjoux G, Lopez F, Esteve JP, Ferrand A, Vivier E, Vely F, Saint-Laurent N, 
Pradayrol L, Buscail L, Susini C 2003 Critical role of Src and SHP-2 in sst2 somatostatin 
receptor-mediated activation of SHP-"	=				Z?			X	
14:3911-3928 
 131.  Lopez F, Ferjoux G, Cordelier P, Saint-Laurent N, Esteve JP, Vaysse N, Buscail L, 
Susini C 2001 Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 
	Z			?	]%	+	"|$__-2302 
 132.  Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, 
Susini C, Buscail L 1999 sst2 somatostatin receptor mediates cell cycle arrest and induction 
of p27(Kip1). Evidence for the role of SHP-"?	+		X	$`"|"-15193 
 133.  Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, 
Peri A, Mantovani G, Bosari S, Beck-Peccoz P, Spada A, Lania A 2006 Octreotide 
promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor 
type 2. Endocr Relat Cancer 13:955-962 
 134.  Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, Vaysse N, 
Susini C, Buscail L 1997 Characterization of the antiproliferative signal mediated by the 
somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A 94:9343-9348 
 135.  Sharma K, Patel YC, Srikant CB 1996 Subtype-selective induction of wild-type p53 and 
apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 
10:1688-1696 
 136.  Sharma K, Srikant CB 1998 G protein coupled receptor signaled apoptosis is associated 
with activation of a cation insensitive acidic endonuclease and intracellular acidification. 
	Z		X	$$"-140 
 137.  Thangaraju M, Sharma K, Liu D, Shen SH, Srikant CB 1999 Interdependent regulation 
of intracellular acidification and SHP-1 in apoptosis. Cancer Res 59:1649-1654 
 138.  Teijeiro R, Rios R, Costoya JA, Castro R, Bello JL, Devesa J, Arce VM 2002 Activation 
of human somatostatin receptor 2 promotes apoptosis through a mechanism that is 
=Z=		=		Z|?	X			"$"-38 
 139.  Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler 
MD, Pradayrol L, Buscail L, Susini C, Bousquet C 2007 Novel synergistic mechanism 
for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-
@ZZ	=	+>	Z?	X			""`-208 
 140.  Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, 
Pradayrol L, Buscail L, Susini C, Bousquet C 2003 Somatostatin receptor subtype 2 
sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad 
Sci U S A 100:155-160 
 141.  Bousquet C, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, 
Fanjul M, Ferrand A, Fourmy D, Pichereaux C, Monsarrat B, Pradayrol L, Esteve JP, 
Susini C 2006 Direct binding of p85 to sst2 somatostatin receptor reveals a novel 
			~>	Z?	*	+	$|-3954 
61 
 
 142.  Hofland LJ, Lamberts SW 2003 The pathophysiological consequences of somatostatin 
receptor internalization and resistance. Endocr Rev 24:28-47 
 143.  Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V, Schulz S 2004 Differential 
beta-arrestin trafficking and endosomal sorting of 	Z	Z?	+		
Chem 279:21374-21382 
 144.  Haraguchi K, Ohtaka M, Takazawa K, Endo T, Onaya T 1995 Desensitization to 
somatostatin analogue (Octreotide) observed in a patient with acromegaly. Endocr J 42:295-
300 
 145.  Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG 2002 Partial tachyphylaxis 
to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor 
desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 146:295-302 
 146.  Fisher WE, Doran TA, Muscarella P, Boros LG, Ellison EC, Schirmer WJ 1998 
Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl 
Cancer Inst 90:322-324 
 147.  Reubi JC, Landolt AM 1989 The growth hormone responses to octreotide in acromegaly 
correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 68:844-850 
 148.  Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, Wass JA, Besser 
GM 1992 Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin 
Endocrinol (Oxf) 36:147-150 
 149.  Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, 
Enjalbert A, Jaquet P $__"	-23244, a somatostatin receptor subtype 2- and 5-selective 
analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-
resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-145 
 150.  Corbetta S, Ballare E, Mantovani G, Lania A, Losa M, Di Blasio AM, Spada A 2001 
Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis 
of gene sequence and mRNA expression. Eur J Clin Invest 31:208-214 
 151.  Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, 
Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR 2007 
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in 
somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65-74 
 152.  Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N, Takekoshi 
S, Sanno N, Teramoto A, Osamura RY 2007 Immunohistochemical detection of 
somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic 
patients: good correlation with preoperative response to octreotide. Endocr Pathol 18:208-
216 
 153.  Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel 
somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) 
receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716 
 154.  Weckbecker G, Briner U, Lewis I, Bruns C 2002 SOM230: a new somatostatin 
peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth 
factor-I axis in rats, primates, and dogs. Endocrinology 143:4123-4130 
 155.  van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin 
V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW 
2004 A single-dose comparison of the acute effects between the new somatostatin analog 
SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 89:638-645 
 156.  Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, 
Hedley-Whyte ET, Stratakis CA, Klibanski A 2006 The effects of SOM230 on cell 
proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J 
Clin Endocrinol Metab 91:4482-4488 
 157.  Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, 
Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, 
Grossman AB, Frohman LA, Bertherat J 2009 Treatment of pituitary-dependent 
X	=			Z	=			Z=	%*$_	
a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122 
62 
 
 158.  Cukier K, Tewari R, Kurth F, Schmid HA, Lai C, Torpy DJ 2009 Significant response 
	Z=	%*$_						Z		Z'		X	
disease. Clin Endocrinol (Oxf) 71:305-307 
 159.  Cescato R, Loesch KA, Waser B, Macke HR, Rivier JE, Reubi JC, Schonbrunn A 2009 
Agonist-=	%			$]	Z		-Somatostatin Analogs KE108 
and SOM230 Activate and Antagonize Distinct Signaling Pathways. Mol Endocrinol 
 160.  Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, 
Enjalbert A, Culler MD 2005 Efficacy of chimeric molecules directed towards multiple 
somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-
secreting pituitary adenomas classified as partially responsive to somatostatin analog 
therapy. Eur J Endocrinol 153:135-141 
 161.  Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, Melmed S 2003 Suppression 
of rat and human growth hormone and prolactin secretion by a novel 
somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 88:5414-5421 
 162.  Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, 
Jaquet P 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine 
'	~-23A387, in suppressing growth hormone and prolactin secretion from 
human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-5552 
 163.  Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for 
dopamine and somatostatin: formation of hetero-oligomers with enhanced functional 
activity. Science 288:154-157 
 164.  Keller ET, Fu Z, Brennan M 2005 The biology of a prostate cancer metastasis suppressor 
protein: Raf kinase inhibitor Z?	+	X		$`-278 
 165.  Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose 
DW, Mischak H, Sedivy JM, Kolch W 1999 Suppression of Raf-1 kinase activity and 
MAP kinase signalling by RKIP. Nature 401:173-177 
 166.  Trakul N, Menard RE, Schade GR, Qian Z, Rosner MR 2005 Raf kinase inhibitory 
protein regulates Raf-"			-	@	?	+		X	$_$"-24940 
 167.  Granovsky AE, Rosner MR 2008 Raf kinase inhibitory protein: a signal transduction 
modulator and metastasis suppressor. Cell Res 18:452-457 
 168.  Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K, Cobb MH 2001 
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. 
Endocr Rev 22:153-183 
 169.  Park S, Yeung ML, Beach S, Shields JM, Yeung KC $__|	>~	=	-Raf 
kinase activity in melanoma cancer cells. Oncogene 24:3535-3540 
 170.  Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirjak 
S, Hanzely Z, Kola B, Korbonits M, Grossman AB 2007 A mutation and expression 
				]		Z	=?	X	=	*Y	-352 
 171.  Lorenz K, Lohse MJ, Quitterer U 2003 Protein kinase C switches the Raf kinase inhibitor 
from Raf-1 to GRK-2. Nature 426:574-579 
 172.  Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR 2006 Raf kinase 
	Z				@	=		Z=	@Z?		X	$|"-
574 
 173.  Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, 
Wyche J, Kolch W, Sedivy JM 2001 Raf kinase inhibitor protein interacts with NF-
@ZZ-inducing kinase and TAK1 and inhibits NF-@ZZ	?		X		
21:7207-7217 
 174.  Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET 2003 Effects of raf 
kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl 
Cancer Inst 95:878-889 
 175.  Akaishi J, Onda M, Asaka S, Okamoto J, Miyamoto S, Nagahama M, Ito K, 
Kawanami O, Shimizu K 2006 Growth-suppressive function of phosphatidylethanolamine-
binding protein in anaplastic thyroid cancer. Anticancer Res 26:4437-4442 
63 
 
 176.  Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK 2004 Reduction in Raf 
kinase inhibitor protein expression is associated with increased Ras-extracellular signal-
regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186-5192 
 177.  Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z 2009 Effects of raf kinase 
inhibitor protein expression on metastasis and progression of human breast cancer. Mol 
Cancer Res 7:832-840 
 178.  Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z 2008 
Effects of raf kinase inhibitor protein expression on metastasis and progression of human 
epithelial ovarian cancer. Mol Cancer Res 6:917-928 
 179.  Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W 
2005 Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer 
metastasis. Clin Cancer Res 11:7392-7397 
 180.  Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott 
L, Fyfe N, Murray GI, Kolch W 2006 Raf kinase inhibitor protein expression in a survival 
analysis of colorectal cancer patients. J Clin Oncol 24:5672-5679 
 181.  Martinho O, Gouveia A, Silva P, Pimenta A, Reis RM, Lopes JM 2009 Loss of RKIP 
expression is associated with poor survival in GISTs. Virchows Arch 455:277-284 
 182.  Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, 
Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, 
Keller ET, Sedivy JM, Yeung KC 2004 RKIP sensitizes prostate and breast cancer cells to 
drug-==	ZZ?	+		X	$`"`|"|-17523 
 183.  Halbleib JM, Nelson WJ 2006 Cadherins in development: cell adhesion, sorting, and tissue 
morphogenesis. Genes Dev 20:3199-3214 
 184.  van Roy F, Berx G 2008 The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 
65:3756-3788 
 185.  Guarino M, Rubino B, Ballabio G 2007 The role of epithelial-mesenchymal transition in 
cancer pathology. Pathology 39:305-318 
 186.  Abe K, Takeichi M 2008 EPLIN mediates linkage of the cadherin catenin complex to F-
actin and stabilizes the circumferential actin belt. Proc Natl Acad Sci U S A 105:13-19 
 187.  Pecina-Slaus N 2003 Tumor suppressor gene E-cadherin and its role in normal and 
malignant cells. Cancer Cell Int 3:17 
 188.  Peinado H, Olmeda D, Cano A 2007 Snail, Zeb and bHLH factors in tumour progression: 
an alliance against the epithelial phenotype? Nat Rev Cancer 7:415-428 
 189.  Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, Sommer T, 
Birchmeier W 2002 Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of 
the E-=	ZY?		X		$$$-231 
 190.  Yilmaz M, Christofori G 2009 EMT, the cytoskeleton, and cancer cell invasion. Cancer 
Metastasis Rev 28:15-33 
 191.  Gavert N, Ben-Ze'ev A 2008 Epithelial-mesenchymal transition and the invasive potential 
of tumors. Trends Mol Med 14:199-209 
 192.  Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen 
P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK 2002 A presenilin-1/gamma-
secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of 
=	?	*	+	$""-1956 
 193.  Ferber EC, Kajita M, Wadlow A, Tobiansky L, Niessen C, Ariga H, Daniel J, Fujita Y 
2008 A role for the cleaved cytoplasmic domain of E-=			?	+		X	
283:12691-12700 
 194.  Kouchi Z, Barthet G, Serban G, Georgakopoulos A, Shioi J, Robakis NK 2009 p120 
catenin recruits cadherins to gamma-secretase and inhibits production of Abeta peptide. J 
	X	$"|-1961 
 195.  Chetty R, Serra S, Salahshor S 2008 Nuclear expression of E-cadherin. Am J Surg Pathol 
32:1269-1270 
 196.  Berx G, van RF 2001 The E-cadherin/catenin complex: an important gatekeeper in breast 
		=		Z?		X		$-293 
64 
 
 197.  Bremnes RM, Veve R, Hirsch FR, Franklin WA 2002 The E-cadherin cell-cell adhesion 
complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 36:115-124 
 198.  Natalwala A, Spychal R, Tselepis C 2008 Epithelial-mesenchymal transition mediated 
tumourigenesis in the gastrointestinal tract. World J Gastroenterol 14:3792-3797 
 199.  Potter E, Bergwitz C, Brabant G 1999 The cadherin-catenin system: implications for 
growth and differentiation of endocrine tissues. Endocr Rev 20:207-239 
 200.  Elston MS, Gill AJ, Conaglen JV, Clarkson A, Cook RJ, Little NS, Robinson BG, 
Clifton-Bligh RJ, McDonald KL 2009 Nuclear accumulation of e-cadherin correlates with 
loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin 
Endocrinol Metab 94:1436-1442 
 201.  Kawamoto H, Mizoue T, Arita K, Tominaga A, Eguchi K, Kurisu K 1997 Expression of 
epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. J Neurooncol 
34:105-109 
 202.  Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, Tashiro T, 
Horiguchi H, Wakatsuki S, Hirokawa M, Sano T 2002 Role of E-cadherin, alpha-, beta-, 
and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod 
Pathol 15:1357-1365 
 203.  Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, Kudo E 2007 Tumor-
specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-
cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 
20:1269-1277 
 204.  Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T 2007 A 
study of the correlation between morphological findings and biological activities in 
clinically nonfunctioning pituitary adenomas. Neurosurgery 61:580-584 
 205.  Gilbert JA, Miell JP, Chambers SM, McGregor AM, Aylwin SJ 2005 The nadir growth 
hormone after an octreotide test dose predicts the long-term efficacy of somatostatin 
analogue therapy in acromegaly. Clin Endocrinol (Oxf) 62:742-747 
 206.  Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA 2005 The value 
of an acute octreotide suppression test in predicting long-term responses to depot 
somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 62:282-
288 
 207.  Pokrajac A, Claridge AG, Shakoor SK, Trainer PJ 2006 The octreotide test dose is not a 
reliable predictor of the subsequent response to somatostatin analogue therapy in patients 
with acromegaly. Eur J Endocrinol 154:267-274 
 208.  Bidlingmaier M 2009 Pitfalls of insulin-like growth factor I assays. Horm Res 71 Suppl 
1:30-33 
 209.  Bidlingmaier M, Freda PU Measurement of human growth hormone by immunoassays: 
Current status, unsolved problems and clinical consequences. Growth Hormone & IGF 
Research In Press, Corrected Proof 
 210.  Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ 2007 Variation in GH 
and IGF-I assays limits the applicability of international consensus criteria to local practice. 
Clin Endocrinol (Oxf) 67:65-70 
 211.  Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S 2004 Central and 
peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 114:349-
356 
 212.  Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ 2009 Pituitary-independent effect of 
octreotide on IGF1 generation. Eur J Endocrinol 160:543-548 
 213.  Lundin P, Pedersen F 1992 Volume of pituitary macroadenomas: assessment by MRI. J 
Comput Assist Tomogr 16:519-528 
 214.  Edal AL, Skjodt K, Nepper-Rasmussen HJ 1997 SIPAP--a new MR classification for 
pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior. Acta Radiol 
38:30-36 
 215.  Fazekas I, Hegedus B, Bacsy E, Kerekes E, Slowik F, Balint K, Pasztor E 2005 
Characterization of human pituitary adenomas in cell cultures by light and electron 
microscopic morphology and immunolabeling. Folia Histochem Cytobiol 43:81-90 
65 
 
 216.  Snyder J, Hymer WC, Wilfinger WW 1978 Culture of human pituitary prolactin and 
growth hormone cells. Cell Tissue Res 191:379-388 
 217.  Reubi JC, Heitz PU, Landolt AM 1987 Visualization of somatostatin receptors and 
correlation with immunoreactive growth hormone and prolactin in human pituitary 
adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 65:65-73 
 218.  Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B 2004 Inhibition of the 
Raf-MEK1/2->"#$		Z'	-xL down-regulation, and chemosensitization 
of non-<=@	Z				Y?	X		`""`-7126 
 219.  Vega MI, Martinez-Paniagua M, Huerta-Yepez S, Gonzalez-Bonilla C, Uematsu N, 
Bonavida B 2009 Dysregulation of the cell survival/anti-apoptotic NF-@ZZ	Z		
		=	-ca anti-CD20 mAb: implication in chemosensitization. Int J Oncol 
35:1289-1296 
 220.  Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G 1998 A causal role for E-cadherin 
in the transition from adenoma to carcinoma. Nature 392:190-193 
 221.  Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G 2007 Tumor progression 
induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. 
Oncogene 26:2290-2298 
 222.  Motti ML, Califano D, Baldassarre G, Celetti A, Merolla F, Forzati F, Napolitano M, 
Tavernise B, Fusco A, Viglietto G 2005 Reduced E-cadherin expression contributes to the 
loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. 
Carcinogenesis 26:1021-1034 
 223.  Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, 
Schally AV, Vaysse N, Susini C, Buscail L 2000 Inhibition of growth and metastatic 
progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) 
gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl 
Acad Sci U S A 97:9180-9185 
 224.  Leu FP, Nandi M, Niu C 2008 The effect of transforming growth factor beta on human 
=		*		Z	=	=		==		
somatostatin signaling. Mol Cancer Res 6:1029-1042 
 225.  Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC 2008 Snail is a 
repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27:2243-2248 
 226.  Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, Yeung K 2008 Novel 
therapeutic applications of nitric oxide donors in cancer: roles in chemo- and 
immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide 19:152-157 
 227.  Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B 2009 
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the 
novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. 
Oncogene 28:3573-3585 
 228.  Chetty R, Serra S, Asa SL 2008 Loss of membrane localization and aberrant nuclear E-
cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg 
Pathol 32:413-419 
 229.  Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R, Woodgett JR 2008 
Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway 
in esophageal squamous cell carcinomas. Mod Pathol 21:271-281 
 230.  Chetty R, Serra S 2008 Nuclear E-cadherin immunoexpression: from biology to potential 
applications in diagnostic pathology. Adv Anat Pathol 15:234-240 
 231.  Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, 
Arosio M, Beck-Peccoz P, Faglia G, Spada A 2001 Mutation of Somatostatin Receptor 
Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment. J Clin 
Endocrinol Metab 86:3809-3814 
 232.  Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, 
Orlando C, Beck-Peccoz P, Spada A 2005 Analysis of Somatostatin Receptors 2 and 5 
Polymorphisms in Patients with Acromegaly. J Clin Endocrinol Metab 90:4824-4828 
 233.  Vender JR, Laird MD, Dhandapani KM $__	~		@ZZ	=		
viability in GH3 pituitary adenoma cells. Neurosurgery 62:1122-1127 
66 
 
 234.  Kucharczak J, Simmons MJ, Fan Y, Gelinas C 2003 To be, or not to be: NF-@ZZ		
the answer--role of Rel/NF-@ZZ					ZZ?	*	$$"-8982 
 235.  Barbera MJ, Puig I, Dominguez D, Julien-Grille S, Guaita-Esteruelas S, Peiro S, 
Baulida J, Franci C, Dedhar S, Larue L, Garcia de HA 2004 Regulation of Snail 
transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 23:7345-
7354 
 236.  Kajita M, McClinic KN, Wade PA 2004 Aberrant expression of the transcription factors 
	=				Z		Y	?		X		$`||-7566 
 237.  Yin T, Wang C, Liu T, Zhao G, Zha Y, Yang M 2007 Expression of Snail in Pancreatic 
Cancer Promotes Metastasis and Chemoresistance. Journal of Surgical Research 141:196-
203 
 238.  Zhuo W, Wang Y, Zhuo X, Zhang Y, Ao X, Chen Z 2008 Knockdown of Snail, a novel 
zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to 
cisplatin via JNK/mitochondrial pathway. Lung Cancer 62:8-14 
 239.  Wu K, Bonavida B 2009 The activated NF-@ZZ-Snail-RKIP circuitry in cancer 
regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit 
Rev Immunol 29:241-254 
 240.  Neil JR, Schiemann WP $__	]=	]"~	@ZZ	@		Z	
transforming growth factor beta-mediated nuclear factor-@ZZ	ion during breast 
cancer progression. Cancer Res 68:1462-1470 
 241.  Neil JR, Johnson KM, Nemenoff RA, Schiemann WP 2008 Cox-2 inactivates Smad 
signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent 
mechanisms. Carcinogenesis 29:2227-2235 
 242.  Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, 
Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, 
Dubinett SM 2006 Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin 
E(2) induc	Z	Z	"	=			-small cell lung cancer. Cancer 
Res 66:5338-5345 
 243.  Huang MT, Chen ZX, Wei B, Zhang B, Wang CH, Huang MH, Liu R, Tang CW 2007 
Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination 
of celecoxib and octreotide. Acta Pharmacol Sin 28:1842-1850 
 244.  Tang C, Liu C, Zhou X, Wang C 2004 Enhanced inhibitive effects of combination of 
rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer 112:470-474 
 245.  Zhou Y, Ran J, Tang C, Wu J, Honghua L, Xingwen L, Ning C, Qiao L 2007 Effect of 
celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. 
X			$-275 
 246.  Onguru O, Casey MB, Kajita S, Nakamura N, Lloyd RV 2005 Cyclooxygenase-2 and 
thromboxane synthase in non-endocrine and endocrine tumors: a review. Endocr Pathol 
16:253-277 
 247.  Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, Livingston EH, Huerta-Yepez S, 
Bonavida B 2009 In vitro and in vivo sensitization of SW620 metastatic colon cancer cells 
to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. 
Nitric Oxide 20:182-194 
 248.  Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B 2009 Pivotal roles of snail 
inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell 
chemoimmunosensitization. Cancer Res 69:8376-8385 
 
 
I
This article is removed. 

II
This article is removed. 

III
This article is removed. 

